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ABSTRACT 
 
Structural and Functional Investigation of Human Chemokines and Applications of 
Human Chemokines in Blocking HIV-1 Entry. 
(December 2007) 
Hongjun Jin, B.Sc., Lanzhou University, Lanzhou, China; 
B. M., Beijing University of Chinese Medicine, Beijing, China 
Chair of Advisory Committee: Dr. Patricia J. LiWang 
 
            Chemokines are important mediators of leukocyte migration. Chemokines bind 
to G protein–coupled receptors (GPCR) and cause conformational changes that trigger 
intracellular signaling pathways involved in inflammation, injury healing, cancer, 
metastasis, and HIV infections. No direct structural information about any chemokine 
receptor is available, but the structure of chemokines has been well studied. Structural 
studies of chemokines coupled with cell-biological investigations may lead to a better 
understanding of the mechanisms of chemokine-receptor interactions. In this Ph.D. 
project, I studied the structural and functional relationship between chemokines and 
chemokine receptors using NMR, X-ray crystallography, and mutagenesis approaches,  
coupled with several different cell-biology assays.  We found that the conserved 
“chemokine fold” can support different dimerization types in the chemokines family, 
although changing the dimers from CC- to CXC-type fold is not readily accomplished. I 
also used an engineered covalently-bound dimer of the MIP-1β mutant, MIP-1β-A10C, 
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to study the relationship between dimerization of chemokines and their interaction with 
the CCR5 receptor. My results suggest that MIP-1β dimer neither bind nor activate the 
CCR5 receptor. I also studied the biophysical properties of one N-terminal awkward 
mutant of P2-RANTES, which was originally selected by others from a phage display 
using CCR5-expressing cells. Although the NMR and X-ray crystal studies revealed that 
the wild type RANTES is a tight homodimer, analytical ultracentrifugation reveals that 
P2-RANTES is a monomer in solution, the 1.7 Å resolution X-ray crystal structure of 
P2-RANTES was found to be a packed tetramer. The mutated N-terminal residues play a 
very important role in the tetramerization in the X-ray crystal structure. Finally I used 
the HIV-1 env mediated cell-cell fusion assay to study the combination of chemokines or 
chemokine variants with anti-HIV peptides C37 or/and T-20. A surprisingly synergistic 
effect was found between P2-RANTES and C37 or T-20.  This combination stratagem 
may lead to further useful drug combinations or drug delivery for more potent anti-HIV 
treatments.  
 
 
 
 
 
 
 
  
v
DEDICATION 
 
To 
My family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
vi
ACKNOWLEDGEMENTS 
 
              I would like to thank my adviser Dr. Patricia LiWang for the support and the 
opportunity to work in her research group. For this, I will be eternally grateful. I thank 
Drs. Nick Pace, Michael Manson and Jerry Tsai for serving as members of my 
committee. To Dr. David Giedroc who was my former committee member. To my group 
members who taught me many things during the group meetings and helpful discussions.  
             I thank Dr. Marc Alizon for offering us the cell lines HeLa-ADA and HeLa-P5L. 
I thank Dr. James C. Hu for assistance with the λ repressor selection system. I thank Dr. 
Pingwei Li for help us calculating the X-crystal structure. I also thank Joshua Hamilton, 
Dr. Melissa A. McCornack for very helpful discussions.  I thank Dr. Amanda Jacks for 
technical assistance. I thank Jake Dennis for the technical support and helpful 
discussions. I thank Carl Carruthers for looking through my thesis. I thank Dr. Lawrence 
J. Dangott and Sabrina N. Schmidtke from the Protein Chemistry Lab at Texas A&M 
University, Department of Biochemistry & Biophysics for the MALDI-TOF Mass 
experiments. I thank Dr. Karl Koshlap and Dr. Xiangming Kong for the technical 
support on the NMR experiments. I thank Dr. Roger Smith for the technical support of 
the FACS experiments.  
 
  
vii
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  iii 
DEDICATION ..........................................................................................................  v 
ACKNOWLEDGEMENTS ......................................................................................  vi 
TABLE OF CONTENTS ..........................................................................................  vii 
LIST OF FIGURES...................................................................................................  ix 
LIST OF TABLES ....................................................................................................  xii 
CHAPTER 
 I INTRODUCTION................................................................................  1 
                          Background .....................................................................................  1 
 II INVESTIGATION OF CC AND CXC CHEMOKINE  
                     QUATERNARY STATE MUTANTS.................................................  24 
   Introduction ....................................................................................  24 
   Experimental Procedures................................................................  27 
   Results ............................................................................................  35 
                           Discussion………………………………………………………… 51 
 III THE HUMAN CC CHEMOKINE MIP-1β DIMER IS NOT 
                     COMPETENT  TO   BIND TO THE CCR5 RECEPTOR ..................  54 
                           Introduction ....................................................................................  54 
   Experimental Procedures................................................................  56 
   Results ............................................................................................  63 
                           Discussion ......................................................................................  77 
         IV        BIOPHYSICAL STUDIES OF POTENT ANTI-HIV CHEMOKINE     
                     MUTANT  PROTEIN P2-RANTES....................................................  80 
   Introduction ....................................................................................  80 
  
viii
   CHAPTER                                                                                                                 Page                            
   Experimental Procedures................................................................  82 
   Results ............................................................................................  92 
                           Discussion………………………………………………………       113 
 
V STRONG SYNERGY BETWEEN CC CHEMOKINES AND 
            FUSION INHIBITORS LEADS TO POTENT EFFECTIVE  
            ANTI-HIV-1 AGENTS IN BLOCKING CELL-CELL  
                     FUSION AND VIRUS INFECTION...................................................    116 
   Introduction ....................................................................................    116 
   Experimental Procedures................................................................  117 
   Results ............................................................................................  126 
                           Discussion………………………………………………………...    136 
 
VI SUMMARY AND CONCLUSIONS...................................................  138 
NOMENCLATURE..................................................................................................  141 
REFERENCES..........................................................................................................  144 
VITA .........................................................................................................................  161 
  
ix
LIST OF FIGURES 
 
                                                                                                                                       Page 
 
 Figure 1-1   An overview of the biological action of chemokines......................  3 
 Figure 1-2   CC chemokines and CXC chemokines share similar “chemokine  
                          fold”  monomeric structure, but have distinct dimer structures ......  6 
 Figure 1-3   The residues of MIP-1β that make critical contacts with CCR5.....  11 
 Figure 1-4   Schematic diagram of CCR5 residues implicated in  
                          chemokine binding by previous publications..................................  14 
 Figure 1-5   A simplified diagram of the multiple steps for HIV fusion to  
                          human cell .......................................................................................  16 
 Figure 1-6   Diagram of N-terminal modifications of RANTES that result in 
                          increased anti-HIV potency.............................................................  18 
      Figure 1-7   Amino acid sequences of HIV fusion inhibitors .............................  21 
      Figure 1-8   Model of HIV fusion and the proposed combination effect............  23 
      Figure 2-1   Ribbon diagram of the dimer structure of MIP-1β and IL-8...........  25 
      Figure 2-2   Ribbon diagram of a model of the designed variant MIP-START..  34 
      Figure 2-3   Analytical ultracentrifugation data of IL-8_86 (left) and 
                          IL-8_A13 (right)..............................................................................  37 
      Figure 2-4   Size exclusion chromatography of the λ repressor (cI)-fused  
                          chemokine variants..........................................................................  50 
      Figure 3-1   MIP-1β-A10C is a covalent dimer ..................................................  64 
      Figure 3-2   MIP-1β-A10C has a nearly identical structure to wild type  
                          MIP-1β ...........................................................................................  65 
      Figure 3-3   MIP-1β-A10C has identical dimer contacts as MIP-1β WT...........  67 
      Figure 3-4   Selected dimer contacts that were observed in MIP-1β-A10C 
                          by 3D NOESY spectra ....................................................................  68 
      Figure 3-5   MIP-1β-A10C does not bind CCR5................................................  71 
      Figure 3-6   Only Cy10 is reduced in 1 mM DTT ..............................................  74 
  
x
                                                                                                                                       Page 
 
      Figure 3-7   Heparin sepharose chromatography of several dimerization  
                          variants of MIP-1β ..........................................................................  76 
      Figure 4-1   Characterization of purified P2-RANTES on MALDI-TOF  
                          Mass spectrum.................................................................................  85 
      Figure 4-2   In the NMR-HSQC experiments each peak conresponds to each     
                          covalently bonded 15N-1H pair in the protein..................................  93 
      Figure 4-3   Dose depedent inhibition curve in the R5-tropic cell-cell fusion 
                          assay with or without the competitive 3T3 cells .............................  95 
      Figure 4-4   CCR5 internalization induced by wild type RANTES and  
                          P2-RANTES in the steady-state CCR5 down modulation  
                          FACS experiment ............................................................................  97 
      Figure 4-5   Heparin sepharose chromatography of wild type RANTES  
                          and P2-RANTES .............................................................................  99 
      Figure 4-6   Oligomerization state of P2-RANTES in solution..........................  101 
      Figure 4-7   AUC sedimentation velocity experiment showing boundary 
                          movements in the plot of absorbance at 280nm versus the  
                          radius in cm .....................................................................................  102 
      Figure 4-8   Species population versus molecular weight by converting the  
                          raw sedimentation velocity data ......................................................  102 
      Figure 4-9   Structure of P2-RANTES................................................................  104 
      Figure 4-10 Close-up view of N-terminal residues of P2-RANTES  
                          monomer A .....................................................................................  104 
      Figure 4-11 Close-up view of the contact interface between Phe0 of  
                          monomer A and the hydrophobic cleft of monomer C ...................  106 
      Figure 4-12 Close-up view of the contact interface between monomer  
                          B (cyan) and monomer C (green)....................................................  106 
      Figure 4-13 Overlay of monomer structure of P2-RANTES (red) to  
                          Met-RANTES (grey) and AOP-RANTES (purple) ........................    109 
  
xi
                                                                                                                                       Page 
 
      Figure 4-14 Overlay of the dimer structure of P2-RANTES to Met-RANTES  
                          and AOP-RANTES .........................................................................  112 
      Figure 5-1   The dose dependent inhibition curve in the R5-tropic cell-cell  
                          fusion assay for combination of chemokines with C37 ..................  125 
      Figure 5-2   The dose dependent inhibition curve in the R5-tropic cell-cell  
                          fusion assay for combination of chemokines with T-20 .................  127 
      Figure 5-3   The dose dependent inhibition curve in the R5-tropic cell-cell  
                          fusion assay for combination of P2-RANTES with C37 or T-20 ...  130 
      Figure 5-4   HIV (Ba-L) infection assay of combination of P2-RANTES  
                          with C37 (10 to 1 ratio) ...................................................................  133 
      Figure 5-5   CCR5 internalization, as measured by FACS .................................  135 
 
 
 
 
 
 
  
xii
LIST OF TABLES 
                                                                                                                                  Page 
 Table 2-1 The amino acid sequences of the rational (designed) mutants  
                        and the phage system-selected chemokine random variants .............  42 
 Table 2-2 Results of the λ phage homodimer repressor selection system  
                        screen for random variants of MIP-1β and IL-8    ...........................      44 
 Table 2-3 The summary of molecular weight and dimerization state of IL-8  
                        and MIP-1β mutants in this chapter ..................................................  47 
      Table 3-1 Intermolecular NOE contacts observed for MIP-1β-A10C ..............  69 
      Table 4-1 Data collection and refinement statistics...........................................  87 
      Table 4-2 The buried surface area of the dimer interface .................................  108 
      Table 5-1   Combination index values for the T-20 (and /or C37) in  
                        combination (1 to 1 ratio) with MIP-1β, RANTES and  
                        P2-RANTES in the HIV-1 (ADA) env mediated  
                        cell–cell fusion ..................................................................................  128 
      Table 5-2 Combination index values and dose reductions for inhibition of  
                        HIV-1 (ADA) env mediated cell-cell fusion with combination 
                        of  P2-RANTES and C37 with different molar ratio.........................  132 
      Table 5-3 Combination index values and dose reductions for inhibition of  
                        HIV-1 (Ba-L) infection assay with the combination of  
                        P2-RANTES with C37 (10 to 1 ratio) ...............................................  133 
 
 
 
 
 
 
 
  
1
CHAPTER I 
INTRODUCTION 
 
Background 
     The word chemokine is an abridged version of chemotactic cytokine. All chemokines 
belong to the cytokine superfamily. Chemokines are widely involved in leukocyte traffic 
and are produced by leukocytes and cells either constitutively or after induction by 
cytokines. Based on the way chemokines are produced, they can be separated into two 
different types: homeostatic and homeorhetic chemokines (1-4).  Some chemokines 
control cells of the immune system during immune surveillance and are secreted without 
any stimulation of the cell that produce them. These are known as homeostatic 
chemokines. Other chemokines have roles in development: they promote angiogenesis 
(the growth of new blood vessels) or guide cells to tissues that provide specific signals 
critical for cellular maturation. These chemokines are known as homeorhetic 
chemokines.  
     The major role of chemokines is to guide the migration of leukocytes. In general, cell 
migration in response to chemokines includes several sequential steps involving 
adhesion molecules, glycosaminoglycans (GAGs), chemokines, and chemokine 
receptors (5,6). First, adhesion molecules on the endothelium interact with mucin 
receptors on the leukocyte, causing a rolling behavior of the leukocyte along the cell 
surface (7,8).  Secondly, chemokines, secreted  in response  to  signals  such  as proinfla-  
This dissertation follows the style and format of  The Journal of Biological Chemistry. 
  
2
-mmatory cytokines, are thought to bind GAGs on the endothelial cell surface, forming a 
chemokine gradient that retains leukocytes at the inflammatory site (9). Thirdly, the 
chemokine gradient provides a direction for the cell’s movement. Interaction of 
chemokines with their receptors on the leukocytes then triggers intracellular signals that 
result in the migration of leukocytes from the blood vessel into the tissues. Finally, firm 
adhesion and extravasation of leukocytes occur along the chemokine gradient (Figure 1-
1).  
Chemokine and chemokine receptors 
   Chemokines are normally small (7-14 kDa) structurally related proteins. Based on 
the arrangement of N-terminal cysteine residues, chemokines can be divided into two 
major subfamilies, named CC and CXC, depending on whether the first two cysteine 
residues are adjacent (CC), or have an amino acid between them (CXC).   Two small 
groups, CX3C chemokines (10) and C chemokines (11) also have been identified. To 
date, approximately 50 human chemokines and 20 chemokine receptors have been 
discovered (1).  There have been at least 28 members of the CC chemokine subgroup 
ligands (CCL)-1 to -28 reported in humans. CC chemokines induce cellular migration by 
binding to and activating CC chemokine receptors, ten of which have been discovered to 
date and named CCR1-10. These receptors are expressed on the surface of different cell 
types to allow these cells to be attracted by chemokines (6, 15). For example, CCL5 (or 
RANTES) attracts cells such as macrophages (monocytes), eosinophils,  and basophils, 
which express the receptor CCR5, CCR1 and CCR3 respectively.  CCL4 (or MIP-1β) 
attracts mainly macrophages (monocytes) that express the CCR5 receptor. 
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Figure 1-1: An overview of the biological action of chemokines.  Chemokines (blue circles) 
form a concentration gradient by binding the glycosaminoglycans (small green diamonds) on 
the endothelium.  Leukocytes (pink) detect the chemokines by binding them tightly using 7-
transmembrane chemokine receptors (purple). The cells  chemotax along the chemokine 
gradient, moving to the point of inflammation or infection. 
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     In humans, 17 different CXC chemokines have been described (1). They are 
subdivided into two categories: those with a specific amino acid sequence of glutamic 
acid-leucine-arginine (ELR for short) immediately before the first cysteine of the CXC 
motif (ELR-positive), and those without an ELR motif (ELR-negative). ELR-positive 
CXC chemokines specifically induce the migration of neutrophils and interact with 
chemokine receptors CXCR1 and CXCR2. An example of an ELR-positive CXC 
chemokine is interleukin-8 (IL-8), which induces neutrophils to leave the bloodstream 
and enter into the surrounding tissue. Other CXC chemokines that lack the ELR motif, 
such as CXCL13, tend to be chemoattractants for lymphocytes. CXC chemokines bind 
to CXC chemokine receptors, of which seven have been discovered to date, designated 
CXCR1-7.  
     Two chemokines have been described for  the C chemokine subgroup called XCL1 
(lymphotactin-α) and XCL2 (lymphotactin-β) (6,15). These chemokines attract T- cell 
precursors to the thymus through interaction with the receptor XCR1. The only CX3C 
chemokine discovered to date is called fractalkine (or CX3CL1) (6,15). It is both 
secreted and tethered to the surface of the cell that expresses it, thereby serving both as a 
chemoattractant and as an adhesion molecule through interaction with the CX3CR1 
receptor. 
Tertiary structure and quaternary structure of chemokines 
     Sequence homology of chemokines is highly variable, ranging from less than 20% to 
over 90%, but all share very similar tertiary structures. Structures of many chemokines 
have been solved by NMR and X-ray crystallography, including: IL-8 (12,13), MIP-
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1β (14), RANTES (15,16), MCP-1 (17,18), eotaxin (19), CX3CL1 (20), PF-4 (21), IP-
10/CXCL10 (22), MCP-2 (23), and vMIP-II (24). These structures reveal that all 
chemokines adopt a remarkably conserved tertiary structure consisting of a disordered N 
terminus of 6–10 amino acids that functions as a key signaling domain in all chemokines 
characterized to date. This region is followed by a long loop (the N-loop) that ends in a 
3-10 helix and invariably contains important binding determinants, a three-stranded β-
sheet, and a C-terminal helix. Disulfide bonds stabilize the overall topology (25). 
Oligomerization of chemokines 
     Many chemokines form dimers and higher-order oligomers alone in solution or upon 
binding to GAGs (26-29). The dimers fall into two very different classes. CC chemokine 
dimers have a completely different organization than CXC chemokine dimers (14,25). 
The N-terminal residues of the CC chemokine MIP-1β  are involved in the dimer 
interface, with residues Pro8 and Phe13 making several critical dimer contacts (Figure 1-
2). The C-terminal helix from each monomeric subunit of MIP-1β points away from the 
other and makes no contact with the other subunit. On the other hand, the dimer of the 
CXC chemokine IL-8 consists of monomeric subunits that interact with each other along 
the first β strand, from residue 23-30, rather than acting on the other side of the molecule 
at the N-terminus (Figure 1-2).  In contrast with the MIP-1β dimer, the C-terminal helix 
of IL-8 makes several critical dimer contacts with the other monomeric subunit. The 
overall shape of the dimer of the CC chemokine MIP-1β is elongated and cylindrical, but 
the dimer of the CXC chemokine IL-8 is compact and globular.  Subsequenct chemokine 
structures have exhibited these same structural properties, with rare exceptions (18,30):   
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Figure 1-2: CC chemokines and CXC chemokines share similar “chemokine fold” 
momoneric structure, but have distinct dimer structures. Top: Overlay of the ribbon 
diagrams of a monomeric subunit of MIP-1β (purple) and IL-8 (magenta). Bottom 
Left: The N-terminal residues of MIP-1β are involved in the dimer interface, with 
residues Pro8, Phe13, and the 40’s loop making critical dimer contacts. Bottom 
Right: The IL-8 dimer consists of monomeric subunits that interact with each other 
along the first β strand (β1) from residues 23 to 30. In contrast with the MIP-1β
dimer, the C-terminal helix of IL-8 makes several critical dimer contacts with the 
other monomeric subunit. The PDB coordinates used for this Figure are 1hum 
(MIP-1β) and 1il8 (IL-8). 
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although not all chemokines are dimers, each CC chemokine that dimerizes shares the 
dimer arrangement of MIP-1β (15,17,18,31).  Likewise, the CXC chemokines that 
dimerize share the dimer structure of IL-8 (32-34).  Therefore, the chemokine 
monomeric fold clearly supports two different dimer structures (Figure 1-2).   
     Given that chemokines from all subfamilies share a common monomeric fold 
regardless of quaternary structure and that this monomer can naturally form two 
different types of dimers, there are likely to be changes in their sequences that will allow 
changes in quaternary structure. In chapter II of my thesis, I described the use of site-
directed mutagenesis (structure based design) and random mutagenesis to study the 
interactions responsible for chemokine dimer formation.   
     A few chemokines are known to form tetrameric structures. Although the structure of 
MCP-1 was initially solved as a dimer in solution by NMR, subsequent crystallographic 
studies revealed the presence of both dimers and tetramers in two different crystal forms 
(18). Earlier studies of PF-4 showed a similar tetrameric architecture as the dominant 
form of the protein in solution (21). In the case of IP-10, two different tetramers were 
observed by crystallography, one similar to the MCP-1 and PF-4 tetramers and the other 
consisting of a novel 12-stranded β-sheet structure (22). Other chemokines, such as 
RANTES, MIP-1α, and MIP-1β, aggregate into even higher- order oligomers (35). For 
this reason, structures of these chemokines were solved at low pH, which destabilizes the 
aggregated form but leaves the CC dimer intact. Therefore, the  dimers are likely the 
fundamental oligomeric subunits of the higher-order aggregates. 
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Tetramers are likely to be the next level of organization,  and the higher-order structures 
are likely organized assemblies rather than random precipitates.                 
     Although the dimerization and oligomerization of chemokines have been attractive 
for structural studies, some functional studies revealed that chemokines interact with 
receptors as monomers. This finding was demonstrated with structure-based design of 
mutants that are obligate monomers. For example, Clark-Lewis et al. made a synthetic 
variant of IL-8 containing a methyl group on the amide of Leu25, which inhibits 
hydrogen bonding between the central β-strands of opposing subunits in the dimer. The 
mutant does not dimerize; nevertheless, the receptor binding affinity of the variant and 
its ability to induce cell migration and release in vitro are equivalent to the wild-type 
protein (36,37). Of note, during my Ph. D. studies, based on the bioinformatics design by 
Dr. Jerry Tsai’s group in our department, I also made a mutant on IL-8 in which two 
residues (R26 and V27) in the middle of the β strands are deleted. This mutant was 
found to be a folded monomer in solution (data not shown).  Although we have not 
checked the biological function of this mutant, it at least stands as an alternative way to 
make an obligate monomer mutant for IL-8. A similar chemical modification of Thr8 in 
RANTES produced a monomeric variant with in vitro activity equivalent to the wild-
type protein (9).  
     Two different strategies were used with MCP-1 and MIP-1β to make monomers. In 
the recombinant forms of these chemokines, substitution at Pro8, a residue that flanks 
the dimer interface and is present in many CC chemokines, results in variants that do not 
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dimerize (38,39). Like IL-8 and RANTES, these mutants also displayed in vitro binding 
and chemotaxis ability equivalent to their wild-type counterparts. This suggests that the 
chemokine monomer is the active form of the protein. But these “trapped” monomers do 
not exclude the possibility that a dimer chemokine could still bind to the receptor. Since 
several studies have produced controdictory results about this possibility (38,40-43), a 
“trapped” dimer would be useful to answer this question. In my research project 
(Chapter III), a trapped dimer was made by a single substitution at the dimer interface. 
We studied the function of this dimer in CCR5 receptor activation and binding. Our 
results clearly show that the dimer does not bind or to activate CCR5. Our studies clarify 
this matter and directly answer the question that normal physiological experiments have 
had difficulty answering. 
Binding and activation of the chemokine receptor by chemokines  
     In pioneering studies on IL-8 using domain-swapping approaches, it was shown that 
there are two major sites of interaction between a chemokine and its chemokine receptor 
(42). The “two-site model” was quickly supported by many other chemokine-chemokine 
receptor studies and became a general model for chemokine binding and activation (43, 
44). Briefly, in this model there are two spatially separate sites on the receptor, one in its 
extracellular domain, the other in its transmembrane domain. These are engaged by two 
separate sites on the chemokine: the first on the surface of the core region and the second 
located in the flexible N-terminal region. The first interaction shows high affinity and 
specificity and is responsible for the correct “addressing” of a chemokine to its receptor. 
It is also responsible for orienting the chemokine in such a way as to favor the second 
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interaction, which is responsible for the “message” function; namely induction of the 
conformational changes in the receptor that lead to signal transduction.   
Receptor-binding sites on chemokines 
     A large number of studies have defined receptor-binding sites on chemokines. By 
generating N-terminal truncation mutants, studies demonstrated the crucial role of the N-
terminus in both binding and signaling. For example for the CXC chemokine IL-8, an N-
terminal deletion mutant had a greater than 10,000-fold loss of binding affinity for 
neutrophils and was completely inactive biologically (44). Later studies also showed that 
specific residues in the N-loop (Y13, Phe17, Phe21) were important for receptor binding 
and specificity, but that the C-terminal helix was not (45).  For the CC chemokines MIP-
1α, RANTES, MCP-1 and MIP-1β, similar results were discovered by the LiWang 
group and other colleagues (46-49). Of all these epitopes, it seems that the aromatic 
residues on the 13th position (F13 or Y13) contribute most to receptor binding. For 
example, in MIP-1β,  when Phe13 is mutated to Ala, the affinity for CCR5 is reduced by 
a factor of ~1000 compared to the WT protein. However, in contrast to the high affinity 
contributed by the IL-8 N-terminus, deletion of N-terminal amino acids in a variant 
referred to as MIP(9) produced only a small reduction in binding,  but activation was 
completely lost (50). This indicates that the N-terminus of CC chemokines may not be 
important for binding, but rather for activation. Similar results were reported for 
RANTES and MCP-1(46-49). All other receptor-binding epitopes involve basic Arg or 
Lys amino acids on the surface of the core protein MIP-1β (R18, K19, R22, R46, K48),  
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Figure 1-3: The residues of MIP-1β that make critical contacts with CCR5.  NMR 
studies for each mutation confirmed that there is no tertiary structural variation. 
The monomeric form of the protein is shown.  Phe13 (yellow) is the most critical 
residue for binding CCR5.  The other residues (red) show at least a 10-fold 
reduction in binding when mutated (39, 47, 50). 
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and these are not confined to the N-loop but are more broadly distributed over the whole 
surface of the chemokine (Figure 1-3).  Very similar results were reported for RANTES 
and MCP-1 (46-49).   
Chemokine-binding sites on receptors  
     Much less is known about chemokine-binding sites on receptors because of the 
difficulties in determining structures for 7-transmembrane receptors. Several studies 
using receptor chimeras and truncation and point mutants have implicated a role for the 
receptor N-termini in chemokine binding (48,51-55). Additionally, several NMR 
structural studies have been conducted using N-terminal peptides from receptors (56-60). 
It has been observed that affinities between the receptor peptides and chemokines are 
much weaker (i.e., millimolar to high micromolar) than the cellular binding assay (i.e. 
nanomolar). Although we do not know exactly how the receptor interacts with 
chemokines, NMR studies complementing the mutagenesis studies indeed reveal that 
receptor binding occurs on the face of the chemokine that was implicated by 
mutagenesis. For example, in one of these studies, the solution structure of a complex 
between IL-8 and the CXCR1 N-terminal peptides shows the receptor peptide lying in an 
extended form along a hydrophobic cleft of the chemokine (60). Although most of the 
contacts are hydrophobic, three negatively charged residues in the peptide interact with 
basic residues on the IL-8 surface. This structure is consistent with the data from 
mutagenesis studies.  
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      Many of the chemokine receptors are predicted to have tyrosine sulfation sites at 
their N-termini that play an important role in chemokine binding (61-64). The sequence 
contains of tyrosine residues flanked by aspartic acid residues, such as D25Y26D27Y28 in 
CCR2b and D2Y3, Y10D11 in CCR5. Tyrosine sulfation has been positively demonstrated 
for CCR5, CCR2b, CX3CR1, and CXCR4, and was found to enhance chemokine 
binding and HIV entry (61-64). These motifs create highly acidic patches on the 
receptors that presumably interact with complementary basic residues on chemokines. 
     Besides the biomedical mutagenesis and NMR studies, there are also several 
receptor-modeling studies. These modeling studies were generated a crude model of a 
chemokine interacting with its receptor based on the only known GPCR structure: 
bovine rhodopsin (65-68). The key features to note are the interaction of the receptor N-
terminus with the chemokine and the positioning of the chemokine N-terminal signaling 
domain towards the receptor, although the contacts between the signaling domain and 
the receptor are largely unknown. Based on several small molecule modeling studies, 
along with the receptor mutagenesis studies, it is commonly accepted that the N-terminal 
signaling domain inserts into the helices TM2 and TM3 (69-72).  However, in a recent 
study, the N-terminus of MIP-1α was labeled with benzophenone, a photoaffinity cross-
linking agent, and used to covalently label CCR1 (73). After enzymatic and chemical 
cleavage of the complex, autoradiography of a polyacrylamide gel showed that the MIP-
1α N-terminus interacts with the second extracellular loop between transmembrane helix 
4 and 5, within a region spanning residues 178–194. A summary of studies of CCR5  
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Figure 1-4: Schematic diagram of CCR5 residues implicated in chemokine binding by 
previous publications (67,68). The N-terminal residues: D2, Y3, Y10, D11, I12, Y14, Y15 
and E18 (gray stick model) play an important role in  chemokine binding.  The second 
extracellular loop (ECL2, green) is also reported to bind to chemokines through 
hydrophobic interactions. Several residues on TM3 (Y108, F109 and F112 (red stick model)) 
were reported to be critical for activation by small agonists.  Residues on ECL2 (S179, 
Y184, and T195, purple stick model) are correlated with the coreceptor function in R5-
tropic HIV entry. The PDB file (1opw) of modeling structure of human CCR5 was 
published by Liu et al. (66). 
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binding and activation sites are highlighted on the modeling structure of CCR5 in Figure 
1-4.   
Chemokine and HIV entry 
     Chemokines and their receptors have attracted particular interest because of their role 
in HIV/AIDS.  Figure 1-5 shows a simplified diagram of HIV fusion to a host cell.  First, 
the HIV-1 env protein gp120 makes contact with the cell surface receptor CD4, causing 
a structural rearrangement that exposes the viral env protein gp41.  The gp120/CD4 
complex then contacts with the cellular co-receptor (either CCR5 or CXCR4) (74-76).  
Meanwhile, because of the exposure of gp41, an N-terminal fusion peptide (FP, aromatic 
residue rich region) of gp41 inserts into the host cell membrane, eventually pulling the 
membrane surface of the virus close to the membrane surface of the protein by folding 
the N-peptide  (HR1, or NHR) back onto the C-peptide  (HR2, or CHR, Figure 1-5 ) to 
form a “trimer of hairpins” (77). The CCR5 receptor is the major route for primary HIV 
infection in humans, while HIV strains that bind to CXCR4 appear later in the 
progression toward AIDS (78). Therefore, the chemokine ligands for these receptors, 
including MIP-1β, MIP-1α, RANTES, and SDF-1, are able to inhibit HIV infection, 
likely both by sterically blocking the receptor and by causing receptor internalization  
(74-76,79-84).   
     There are several key areas that remain to be explored in investigating the inhibition 
of HIV entry by chemokines.  For example, does the quaternary state or GAG-binding 
ability modulate the effectiveness of chemokines in inhibition?  What characteristics of  
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Figure 1-5: A simplified diagram of the multiple steps for HIV fusion to human cell. There 
are three sequential steps for HIV entry: CD4 binding (attachment), coreceptor (CCR5 or 
CXCR4) binding, and trimer of hairpins fusion. To block HIV entry, three general 
stratagems can be used: blocking CD4-gp120 interaction (Cv-N or CD4 antibodies), 
blocking gp120-chemokine receptors  interaction (MIP-1β, MIP-1α, RANTES or SDF-1)
or blocking gp41 trimer of helix bundle formation (T-20 or C37).  
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the chemokine allow maximal potency in HIV inhibition? Can chemokines be used as 
delivery vehicles for known therapeutics to improve their efficacy? In this Ph.D. project, 
I tried to answer these questions based on the current knowledge from structural and cell 
biology studies, but not all of these can be answered in my Ph.D. studies. The continuing 
studies in the P.LiWang lab will keep investigating all these interesting questions. 
Modified chemokines as HIV inhibitors 
     Since the discovery that certain chemokines were “AIDS-suppressive factors” (82), 
many variants of MIP-1β, MIP-1α and RANTES were made, some to elucidate details 
of the mechanism of action of these proteins (35,39,47,50,85,86) and some to design 
agents with therapeutic potential (87,88).  In the latter category, the vast majority of 
work has been carried out on the CC chemokine RANTES.  In particular, a chemically 
modified form of RANTES called AOP-RANTES, which has a hydrophobic attachment 
at its N-terminus (Figure 1-6), was shown to be very effective at inhibiting HIV infection.  
The mechanism of action was shown to involve both sterica blocking of HIV entry and 
induced endocytosis of the CCR5 receptor (89-92). Other work has shown that receptor 
endocytosis is an important target of this type of HIV inhibitor (79,93), although 
receptor blockage is also a significant component of inhibition (93). 
     Recent work with modified RANTES has resulted in the synthesis of other 
hydrophobic N-terminal modifications to the chemokine, NNY- RANTES (94) and PSC-
RANTES (87,93) (Figure 1-6).  These hydrophobic N- terminally modified chemokines 
show stronger anti-HIV activity because they accelarate removal of  CCR5 from the 
surface of the cell and thereby reduce viral access to cell surface binding sites (92,95-98). 
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Figure 1-6: Diagram of N-terminal modifications of RANTES that result in increased anti-
HIV potency. The numbers in parentheses are the IC50s from the R5-tropic cell-cell fusion  
assays (38,95,99). 
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     Instead of using organic synthesis to modify the N-termini of chemokines,  Hartley et 
al. used mutagenesis to screen potent anti-HIV chemokines through a phage display 
technique (100). The phage-displayed library of randomly mutated and N- terminally 
extended variants was screened by direct exposure to live CCR5-expressing cells. One of 
the modified six-site mutants, P2-RANTES (FSPLSSQSSA-RANTES (aa10-68)), was 
characterized as a super agonist of CCR5 and a potential inducer of receptor 
internalization. P2-RANTES exhibits not only significantly increased affinity for CCR5 
but also enhanced receptor selectivity, retaining only trace levels of signaling activity via 
CCR1 and CCR3. Prior to my research, no structural information was available for this 
chemokine variant. In my Ph.D. studies, I overexpressed, refolded and purified P2-
RANTES from E. coli. A detailed description of its structure is in chapter IV of this 
thesis. 
HIV fusion inhibition 
     In recent years, some of the most promising progress in anti-HIV drug development 
has been abtained with the anti-HIV entry inhibitors. As shown in Figure 1-5, in order to 
block HIV entry, three general stratagems can be used: to inhibit CD4-gp120 interaction; 
to block gp120/41 chemokine receptor (CCR5 or/and CXCR4) interaction; or to prevent 
gp41 six-helix bundle formation.  
     Inhibitors that block the formation of the six-helix bundle represent the newest 
generation of anti-HIV drugs. The six-helix bundle structure of gp41 is comprised of N 
and C-terminal helical heptad repeats (101-103). The peptides corresponding to the HIV 
envelope protein gp41 N-terminal region (HR1) normally are called N-peptides and the 
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peptides corresponding to the HIV envelope protein gp41 C-terminal region (HR2) 
normally are called C-peptides (Figure 1-7). C-peptides and N-peptides are potent 
inhibitors of HIV entry. Their mechanism of inhibition involves binding in a helical 
conformation to the central coiled-coil of gp41 (101-103) to block formation of the 
trimer of hairpin that pulls the viral membrane close to the cell membrane. T-20 (also 
known as DP-178), which corresponds to the C-terminal residues of gp41, was recently 
approved by the FDA. Other C-peptides, such as C34, C36, C37, are also reported to 
have strong anti-HIV activity (101,104). C37, derived from the C-terminus of gp41, 
covering all sequence of C34, in particularly has been reported to have strong anti-HIV 
entry activity, and this peptide can be easily produced through overexpression in E. coli.     
     T-20 and C34 have proven useful in the modeling structural features of gp41, thereby 
revealing their potential to interfere with the pre-heparin formation by binding to the 
hydrophobic groove on the N terminal heptad repeat of gp41 (105). Although T-20 has 
been very successful, clinical trails revealed that the dose required is much higher in vivo 
than in vitro (106,107). The reasons for this higher dosage includes swift proteolysis and 
clearance of the unstructured peptide and non specific binding of T-20 binds to unrelated 
cell membranes or lipids (77,104,108,109) .We have hypothesized that if this small 
peptide can be carried by some delivery system, its specificity will increase.  
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Figure 1-7: Amino acid sequences of HIV fusion inhibitors. A). CC chemokines MIP-1β, 
RANTES, P1-RANTES and P2-RANTES. The conserved Cys motifs are highlighted in 
purple. The six-site mutated residues of P1-RANTES and P2-RANTES are showing in red. 
The right column shows the actual IC50s measured from the R5 tropic cell-cell fusion assay 
(100); B). C-peptides derived from HIV gp41. FP: fusion peptide, HR1: helix region 1 (N-
terminus of gp41), HR2: helical region 2 (C-terminus of gp41), TM: transmembrane region, 
Cyto: cytoplasmic domains of gp41. 
 
 
 
 
 
 
 
  
22
Design of chemokines with improved HIV-1 inhibition characteristics 
     The better structural understanding we have of interactions between chemokines and 
chemokine receptors, the better we will be able to design chemokine variants that inhibit 
HIV entry through both coreceptors interactions and fusion process. For example, it will 
be very interesting to use chemokines as delivery vehicles for known HIV inhibitors 
such as T-20 or C37. 
     Genetic studies revealed that Caucasian individuals bearing mutant alleles of the 
CCR5 chemokine receptor gene CCR5-∆32 mutation (110,111) are resistant to certain 
strains of HIV. These people are resistant to infection with R5 HIV because the defect in 
CCR5 decreases HIV binding to this coreceptor, reducing its ability to infect target cells. 
Similarly, CCR5 internalization are likely to be important aspects of the ability of 
chemokines to inhibit HIV (79,89,91,93).  
     In designing anti-HIV stratagems, we sought to develop a way to harness the ability 
of chemokines to bind to CCR5 with clinically proven peptide T-20. Our hypothesis was 
that T-20 (or other C-peptides, such as C34 and C37) could be administered at much 
lower doses if it were combined with CCR5 or CXCR4-binding chemokines (Figure 1-8).   
     I combined several CCR5-binding chemokines with C-peptides using a cell-cell 
fusion assay, which is a standard in vitro test of HIV fusion. The results indicate that 
there is a strong synergistic effect between these CC chemokines and the C-peptides. 
The strongest synergy was found between P2-RANTES and the C37 peptide. Our 
collaborator tested this combination using the PBMC HIV infection assay, and a 
dramatic synergistic effect was achieved. These results indicate that blocking two 
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activities (CCR5 binding and interrupting of gp41 prehairpin state form) can be 
combined for potent HIV therapeutic effect.  Further details are described in chapter V 
of this thesis. 
 
 
 
 
 
 
 
Figure 1-8:  Model of HIV fusion and the proposed combination effect. Top:  Model 
of HIV fusion to the host cell.  Middle:  The effect of T-20  in inhibiting fusion. 
Bottom:  Proposed synergy of chemokines with T-20 to effectively inhibit HIV-1
entry.  
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CHAPTER II 
INVESTIGATION OF CC AND CXC CHEMOKINE 
QUATERNARY STATE MUTANTS∗ 
 
Introduction 
    Chemokines (chemotactic cytokines) are a group of small (7-14 kDa) structurally 
related proteins that regulate cell trafficking of various types of leukocytes through 
interactions with a subset of seven-transmembrane, G protein-coupled receptors. About 
50 chemokines have now been identified in humans (3,112).  Based on the arrangement 
of N-terminal cysteine residues, chemokines can be divided into two major subfamilies, 
CC and CXC, depending on whether the first two cysteine residues are adjacent (CC), or 
have an amino acid between them (CXC).   Two small groups, CX3C chemokines (10) 
and C chemokines (11) also have been identified.  Due to their role in inflammation, 
chemokines also play a role in many diseases, including atherosclerosis and allergy 
(3,113).  In addition, the HIV co-receptor, CCR5, is actually a chemokine receptor and is 
the natural receptor for the CC chemokines MIP-1α, MIP-1β  and RANTES, making 
these chemokines natural HIV-blocking proteins (74,114).  
     All chemokines have been shown to have a common monomeric fold, the core of 
which is an antiparallel β sheet comprised of three β strands, followed by a C-terminal  
                                                 
 
∗ Reprinted with permission from “Investigation of CC and CXC chemokine quaternary 
state mutants” from (143) Hongjun Jin,Garret L. Hayes, Nithyanada S. Darbha, Erik 
Meyer and Patricia J. LiWang, 2005.  Biochemical and Biophysical Research 
Communications, 338(2): 987-999. Copyright © 2007 Elsevier B.V. 
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Figure 2-1: Ribbon diagram of the dimer structure of MIP-1β and IL-8.  A) The MIP-1β 
dimer and close-ups of selected regions of dimer contact.  The N-terminal residues of MIP-
1β are involved in the dimer interface, with residues Pro8 (a), Phe13 (b) and the 40’s loop 
(c) making several critical dimer contacts. The C-terminal helix from each monomeric 
subunit of MIP-1β points away from the other and makes no contact with the other subunit.  
B) The IL-8 dimer and close-ups of two regions that make intersubunit contact. The dimer 
consists of monomeric subunits that interact with each other along the first β strand (β1) 
from residue 23-30 (a).  In contrast with the MIP-1β dimer, the C-terminal helix of IL-8 
makes several critical dimer interactions with the other monomeric subunit (b).  PDB 
coordinates used for this figures are 1hum (MIP-1β) and 1il8 (IL-8). 
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α-helix.  Many chemokines also form dimers.  However, CC chemokine dimers have a 
completely different organization than CXC chemokine dimers (14,25). The N-terminal 
residues of the CC chemokine MIP-1β  are involved in the dimer interface, with residues 
Pro8 and Phe13 making several critical dimer contacts (Figure 2-1). The C-terminal 
helix from each monomeric subunit of MIP-1β points away from the other and makes no 
contact with the other subunit. On the other hand, the dimer of the CXC chemokine IL-8 
consists of monomeric subunits that interact with each other along the first β strand, 
from residue 23-30, rather than acting on the other side of the molecule at the N-
terminus (Figure 2-1B).  In contrast with the MIP-1β dimer, the C-terminal helix of IL-8 
makes several critical dimer interactions with other monomeric subunit. The overall 
shape of the dimer of the CC chemokine MIP-1β is elongated and cylindrical, but the 
dimer of the CXC chemokine IL-8 is compact and globular.  Later structures of 
chemokines have also exhibited these structural properties with rare exceptions (18,30): 
although not all chemokines are dimers, each CC chemokine that dimerizes shares the 
dimer arrangement of MIP-1β (15,17,18,31).  Likewise, the CXC chemokines that 
dimerize share the dimer structure of IL-8 (32-34).   Therefore, the chemokine 
monomeric fold clearly supports two different dimer structures.  Moreover, functional 
work suggests a biological role for both the dimeric and the monomeric form of the 
chemokine (9,29,37-39,115). 
     Given that chemokines from all subfamilies share a common monomeric fold 
regardless of quaternary structure and that this monomer can naturally form two 
different types of dimer, the hypothesis is made that there are likely to be changes in 
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sequences that will allow changes in quaternary structure, perhaps including allowing 
one stable dimer type to be turned into the other dimer type.  Since MIP-1β and IL-8 can 
be considered to be prototypical CC and CXC chemokines respectively, this hypothesis 
can be tested.  We and others have reported several mutations in MIP-1β and IL-8 that 
allow formation of monomeric variants, although no attempts were made to determine if 
the new monomeric scaffold could support other mutations or form alternate dimer types 
(37-39,116).  
     The present studies report the use of rational mutagenesis (structure based design) 
and random mutagenesis, to allow insight into the interactions responsible for 
chemokine dimer formation.  A combination of nuclear magnetic resonance (NMR) 
spectroscopy, analytical ultracentrifugation, and size exclusion chromatography were 
used to analyze more than 24 MIP-1β and IL-8 variants produced both rationally and by 
the randomization/selection process. 
 
Experimental Procedures 
Production of structure-based design variants 
     For changes at the termini of the proteins (to remove the N-terminal 8 residues from 
MIP-1β, to add C-terminal of IL-8 to MIP(9), to remove 6 residues from C-terminal of 
IL-8, or to add 9 amino acids of  MIP-1β to N-terminal of  IL-8) standard thermocycling 
reactions were carried out with primers encoding the proper change.  To put the β1 
strand of IL8 onto MIP-1β,  PCR mutagenesis was carried out in a two-step reaction by 
using primers according to the β1 strand sequence of MIP(9)-IL-8 β1  combined with N-
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terminal forward primer and C-terminal reverse primer for MIP(9).  The PCR products 
were purified and digested with NcoI and BamH I restriction endonuclease, and cloned 
into the Nco I and BamH I site of vector pET-32a(+) (Novagen). To make the single site 
or multiple site mutations, mutagenesis on IL-8 were carried on using the QuikChange 
(Stratagene) method. All mutations were confirmed by DNA sequencing. 
Plasmids and primers for the randomization library 
     The genes for WT MIP-1β, IL-8, MIP-START (starting point monomeric mutant of 
MIP-1β, designed in the present study) and IL-8-START (starting point monomeric 
mutant of IL-8, designed in the present study) were placed into the screening vector 
JH391 (117) using the BamH I and Sal I restriction sites. Phage stocks were initially 
obtained from the laboratory of Dr. James Hu and propagated as described (118).  The 
phages used were phage λ KH54 and phage λ h80.  Both of these phage stocks are 
deleted for the cI gene and differ only in the recognition of the receptors needed to gain 
initial access to the host cell. Oligonucleotide primers for mutagenesis were ordered 
from IDT (Coralville, IA), with bases to be randomized designated as “N” in the 
sequence.  For randomization of regions within approximately twenty base pairs of the 
5’ or 3’ termini, an overhang PCR was performed to create a library of mutants.  For 
randomization of regions distant from the termini, two separate thermocycling reactions 
were used to accomplish randomization:  Initially, two separate but complementary 
(except for the region of mutation) oligonucleotides were created.  These primers were 
used with terminal oligonucleotide primers to create “half-gene products” that were then 
annealed together in another thermocycling reaction to create a “full-gene product” 
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randomized only in the desired region.  The randomized gene product and the JH391 
plasmid were subjected to restriction digestion by Sal I and BamH I restriction enzymes.  
The randomized inserts and JH391 plasmid were then ligated (10 ng of gene with 100 ng 
of vector). 
Phage selection of random chemokine variants 
     A “cross-streak” test individually examines the success or failure of a particular λ 
fusion partner in conferring resistance to phage infection. First, phage λ KH54 is 
streaked horizontally across an LB agar plate.  Next, streaks of cells from a single colony 
containing a construct to be tested are drawn orthogonal to the phage line.  The vitality 
of the cells after they cross the phage line indicates the presence or absence of a 
functional λ repressor. A method to screen large numbers of random mutants has been 
described (119).  Briefly, ligation mixtures containing the chemokine variants fused to 
the λ repressor in the JH391 vector were transformed using electroporation into AG1688 
E. coli cells and then plated onto agar plates containing λ KH54 and h80 phage. A small 
portion of the transformation mixture was removed and plated under permissive 
conditions (no phage) to allow an assessment of the number of mutants screened. The 
plasmid from surviving colonies was purified and retransformed into AG1688 cells and 
the cells were challenged again with phage to ensure that all colonies harvested from the 
initial high-throughput plate were in fact resistant to phage based on the dimerization of 
λ repressor due to vector-encoded chemokine and not on artifacts of natural selection in 
the E. coli cells.  The gene for a chemokine variant that continually demonstrated the 
ability to convey phage resistance was then shuttled into the pET expression system 
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(Novagen). (MIP-START and its related random mutants were placed into pET32a(+) at 
the Nde I-BamH I sites, and the expressed proteins do not have a histidine tag on the N-
terminus; IL-8-START and its related random mutants were placed into pET15b at the 
Nde I-BamH I sites, and when expressed, these proteins have a 6 histidine tag on the N-
termini to facilitate the purification.)  Purified protein was examined by analytical 
ultracentrifugation, NMR, and/or size exclusion chromatography. 
Construction of cI fusion mutants  
     To construct cI fusion mutants, the gene for cI-MIP-1β WT, cI-MIP-START, cI-IL-8 
WT, cI-IL-8-START and two MIP-START mutations MIP_8S and MIP_8G and one of 
IL-8-START mutation IL-8_86 were amplified from the JH391 vector by using standard 
thermocycling reactions and ligated into pET15b (Novagen) Nde I-BamH I sites, the 
coded protein have the 6XHistag on the N-termini to facility the purification.  
Protein expression and purification   
     For wild type proteins and MIP-1β variants and IL-8 variants from the mutagenesis, 
protein expression and purification followed a standard chemokine refolding and 
purification method published previously (39).  For the cI fusion mutants, a slight 
variation on the procedure was used, in that the proteins were expressed in rich medium, 
and the protein inclusion body was taken up in 50 ml of 6M Guanidine chloride, 20 mM 
sodium phosphate buffer pH 7.2 containing 250 mM NaCl and 10 mM 2-
mercaptoethanol and loaded onto a 5ml chelating column (Amersham Pharmacia 
Biotech) equilibrated with nickel sulfate and the guanidinium buffer.  The protein was 
refolded on the column using a gradient to slowly decrease the amount of guanidine 
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chloride in 20 mM sodium phosphate buffer pH 7.5 containing 250 mM NaCl, then 
eluted with imidazole. The fractions containing refolded protein were pooled together 
and directly diluted 10 fold into 10% acetonitrile and 0.1% trifluoroacetic acid solution, 
and loaded onto an equilibrated C4 reversed phase column (Vydac, Hesperia, CA).  The 
protein was eluted using an acetonitrile/0.1% TFA gradient.  Fractions containing the 
proteins were quickly frozen in liquid nitrogen and lyophilized by the Labconco freeze 
dry system (Labconco Corporation) into dried powder. A small amount of the fractions 
of each run was collected and run on 12% SDS-PAGE to confirm the protein purity. 
Size exclusion chromatography for cI fused chemokine mutants  
     The purified protein powder was first dissolved into 20 mM sodium phosphate buffer 
pH 2.5 containing 150 mM NaCl, and then the pH of the solution was adjusted to 7.2 
with a small amount of 4M NaOH.  The solution was centrifuged at 12000 rpm for 20 
minutes to remove any possible precipitation. The dissolved refolded protein (~ 0.5ml) 
was loaded onto a Superdex G75 gel filtration column (Amersham Pharmacia Biotech) 
equilibrated with 20mM pH 7.2 sodium phosphate buffer containing 150 mM NaCl and 
the protein was eluted with this buffer (for cI-MIP-1β WT elution was carried out with 
20 mM sodium phosphate buffer pH 7.2 containing 500 mM NaCl) and run using the 
Pharmacia Akta system.  The gel filtration column was calibrated with several standard 
marker proteins (BioRad) in the same running buffer, and the molecular weight of cI-
fused chemokines mutants were estimated using the calibrated standard curve.  All 
sample elution was performed at 0.4ml/min, 1ml fractions were collected, and the 
protein content was analyzed by 12% SDS-PAGE.  
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Analytical ultracentrifugation (AUC) 
     Sedimentation equilibrium data were collected on a Beckmann XL-A analytical 
ultracentrifuge  rotor An-60 Ti at 25˚C with multiple speeds and variable protein 
concentration to obtain the molecular weight or dimer dissociation constant of the 
proteins under study. The protein concentrations were determined by absorbance at 280 
nm using the extinction coefficients estimated by the Expasy web server 
(http://us.expasy.org/). Samples were dissolved with 20 mM pH 7.2 (with the exception 
of IL-8-START , IL-8_86 and IL-8_A13  which were dissolved at pH 5.0 to maximize 
solubility) sodium phosphate buffer containing 150 mM NaCl (cI-MIP-1βWT was 
centrifuged in 500 mM NaCl due to its tendency to aggregate at lower salt 
concentrations).  During each equilibrium experiment, samples were monitored by 
absorbance at 280 nm. For each mutant, AUC experiments were done at constant 
concentration with multiple speeds, or with runs at various concentrations with multiple 
speeds:  50µM IL-8-START, 50µM IL-8_A13 and  50µM IL-8_86 run at 26500 rpm and 
37500 rpm; 45µM, 90µM and 180µM MIP-START run at 16000 rpm, 26500 rpm and 
40000 rpm respectively; 30µM MIP-8S and 30µM MIP-68S run at 26500 rpm and 
37500 rpm; 10µM cI-IL-8WT run at 16000 rpm, 26500 rpm; 10µM and 15µM cI-IL-8-
START run at 16000 rpm and 20000 rpm respectively; 20µM cI-IL-8_86 run at 16000 
rpm and 37500 rpm; 20µM cI-MIP-1βWT run at 16000 rpm and 26500 rpm; 10µM and 
12µM cI-MIP-START run at 16000 rpm and 20000 rpm respectively; 30µM cI-MIP_8S 
and 20µM cI-MIP_8G run at 16000 rpm and 26500 rpm respectively. The solvent 
density (ρ) and partial specific volume of the protein( _ v ) were calculated from the amino 
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acid composition using the program Sednterp (obtained from the Boston Biomedical 
Research Institute RASMB web site). The data were processed using the program 
Origin, which is useful  for both detecting multiple equilibria and estimating the value of 
the equilibrium constants from the absorbance data (120).  Each set of experimental data 
was fit to an ideal model or monomer–dimer equilibrium model using a nonlinear least 
squares fit. The data of cI-MIP-1β WT and cI-IL-8 WT fit best to the monomer-dimer 
equilibrium model.  The dimer Kd (disassociation constant) values were calculated using 
a similar method as described by others (121,122). All other proteins fit best with a 
single ideal monomer model, from which was obtained the calculated molecular weight.  
For each mutant, the average molecular weight and standard deviation were calculated 
from multiple experiments. 
Nuclear Magnetic Resonance 
     NMR spectra were acquired at 25 °C on a Varian Unity Plus 500 MHz spectrometer 
equipped with an xyz gradient penta probe. 15N-1H HSQC (heteronuclear single quantum 
coherence) spectra were collected with 512* points in the proton dimension and 128* 
points in the nitrogen dimension. A spectral width of 6000 was used in the 1H dimension 
and 1500.68 Hz for 15N . The samples were placed in Shigemi tubes (Allison Park, PA) 
and the spectra referenced relative to DSS (2,2-dimethyl-2-silapentane-5-sulfonate) 
(123). The data were processed using the program nmrPipe (124) and analyzed using the 
program PIPP (125). For MIP-1β mutants, the samples were dissolved in 10% D2O with 
20mM sodium phosphate, pH 7.2, 100mM NaCl; for IL-8 mutants, samples were 
dissolved  in 10% D2O  solvent with  20 mM  sodium phosphate,  pH 5,  100 mM  NaCl.       
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Figure 2-2: A) Ribbon diagram of a model of the designed variant MIP-START.  In 
addition to truncation of the first 8 residues, two amino acids in the β1 strand were 
mutated (Y28, E30; red) and 4 residues from the C-terminal helix were replaced with 8 
residues from IL-8, lengthening the helix by one turn (green). PDB coordinates used for 
this figure are 1hum.  B) Overlay of the NMR 15N - 1H HSQC spectra of MIP-START and 
all eight folded random variants.  The labeled assignments of MIP-START are inferred 
from similarity to previously published mutants  (50,126).  Each variant is represented 
with different color:  MIP-START (red), MIP_1S (purple), MIP_2S (orange), MIP_8S 
(black), MIP_12S (yellow), MIP_68S (light blue), MIP_1G (green), MIP_4G (lavender) and 
MIP_8G (dark blue). C) Ribbon diagram of a model of the designed variant IL-8-START.  
IL-8-START lacks the last 6 residues of the C-terminus, and also has a T37E mutation 
(purple). The first 9 residues of N-terminal MIP-1β were added onto IL-8–START, as well 
as the Phe13 from MIP-1β (purple). PDB coordinates used for this Figure are 1IL8.  D) 
The 15N - 1H HSQC spectra of two folded IL-8 mutants IL-8_86 (black), IL-8_A13 (purple) 
and IL-8_T37E_6XC (green) overlaid with the spectrum of IL-8-START (red).  The 
labeled assignments of peaks are from IL-8_T37E_6XC (unpublished data).  
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Results 
Structure-based mutagenesis of chemokines to alter quaternary state 
     In a first step toward altering the CC and CXC chemokine dimer, rational 
mutagenesis was employed to both disrupt the natural dimer and to favor formation of 
the dimer of the other subfamily.  It has been shown that removing the N-terminal 
residues of MIP-1β results in a folded, monomeric protein (50), so all MIP-1β variants 
reported here lack the first 8 amino acids.  Since the β1 strand region is critical for IL-8-
type dimer formation, residues 26-31 in MIP-1β were replaced with the analogous 
resides in IL-8.  However, rather than resulting in an IL-8-type dimer, the resulting 
protein was unfolded (data not shown).  The structure of MIP-1β reveals that several β1 
residues participate in important intramolecular contacts, so a more conservative set of 
changes were made in which only Y28 and E30 were mutated to residues analogous to 
their IL-8 counterparts (Y28A and E30V, respectively).  This resulted in a folded, 
monomeric protein (data not shown). Since the β1 variation did not lead to an IL-8-type 
dimer, the other major area of IL-8 dimerization was added to MIP-1β.  As shown in 
Figure 2-1B, the IL-8 C-terminal helix makes critical dimer contacts and the helix is 
longer than that of MIP-1β.  Therefore, in addition to the N-terminal truncation and 
alteration of the β1 strand, the four C-terminal residues of the MIP-1β  helix were 
replaced by eight residues of IL-8 helix, lengthening the helix by one turn.  The resulting 
protein is diagrammed in Figure 2-2A and the NMR spectrum is shown in Figure 2-2B.  
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While the extensively altered MIP-1β variant was successfully produced as a folded 
protein, it was found to be a monomer, with no affinity for either dimer type.  
     In our study of the quaternary state of IL-8, we first focused on mutations in the β1 
strand, since this region forms the center of the dimer interface (Figure 2-1B).  
Mutations were made to the β1 strand (L25A/V27E), resulting in a weakened dimer that 
was in equilibrium with the monomeric form.  This suggests that the β1 strand provides 
dimer stability through both backbone interactions and side chain interactions (data not 
shown).  A more successful strategy for making purely monomeric IL-8 was to remove 
the critical dimer contacts made by the C-terminal helix.  This was accomplished by 
employing the double strategy of shortening the helix by 6 residues (first suggested to 
weaken the dimer by Rajarathnam et al. (127)) and simultaneously mutating Thr37, a 
residue in the 30’s loop that contacts the helix from the other subunit (shown to be 
involved in the dimer (128)) (Figure 2-1B).  These mutations resulted in a folded, wholly 
monomeric variant of IL-8 (Figure 2-2D).   
     To attempt to form a MIP-1β-type dimer with monomeric IL-8, the N-terminus of 
this IL-8 variant was replaced with the N-terminus of MIP-1β.  The vast majority of 
MIP-1β dimer contacts are made by its N-terminal region, particularly residues Pro8 and 
Phe13 (Figure 2-1A), so the IL-8 variant replaces residues1-7 with the first 9 residues 
from MIP-1β, and also includes Phe13 from MIP-1β (while retaining the structurally 
necessary N-terminal CXC of the original IL-8).  However, despite the extensive 
mutation to this protein, analytical ultracentrifugation shows it to be a monomer  
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Figure 2-3: Analytical ultracentrifugation data of IL-8_86 (left) and IL-8_A13 (right).  For 
each panel, the lower plot shows the raw data and the best fit to a specific model. The 
upper plot shows residuals from fitting the model.  The estimated molecular weight 
includes the N-terminal histidine tag.  The number shown in table 2-3 differs slightly 
because it shows the average value obtained from multiple runs.  The line denoted “dimer” 
is for comparison and indicates a curve that would be obtained for a monomer-dimer 
equilibrium.  
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(Figure 2-3).  This mutant was termed “IL-8-START” for the random mutagenesis 
described below.   
Random mutagenesis and dimer selection 
     Since structure-based mutagenesis provided many sequences that remained folded but 
were monomeric, it was decided to randomly mutate a monomeric starting point from 
each protein to determine whether alternate dimers could be formed or whether even 
more monomeric variants were possible.  The final MIP-1β variant described above was 
designated MIP-START for the purposes of random selection (Figure 2-2A describe the 
full set of mutations to make MIP- START).  Since this variant lacks the first eight 
residues of the N-terminus, no mutation is likely to cause reversion back to a wild-type 
MIP-1β dimer.  Therefore, any dimers produced by randomization would likely be either 
similar to IL-8 or an equally interesting alternate arrangement.  As described above, 
MIP-START already contains some elements of the IL-8 dimer structure that might, 
upon further mutation, help promote the formation of the IL-8-type dimer.  Similarly, the 
IL-8 variant ultimately described above was designated IL-8-START  (Figure 2-2C 
describe the full set of mutations to make IL-8-START) and was chosen as the 
beginning chemokine variant for randomization.  Since IL-8-START lacks the last 6 
residues of the C-terminus, randomization is unlikely to cause reversion back to a wild-
type IL-8 dimer because it is unlikely that the shortened C-terminal helix can reach the 
other subunit to make dimer contacts.  Therefore, any dimers produced by randomization 
would likely be either structurally similar to MIP-1β or an interesting alternate 
arrangement. 
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The λ phage selection system 
     Several strains of bacteria are susceptible to infection by λ phage, which eventually 
causes host bacterial cell death by cell lysis. However, cells are able to survive infection 
by phage if the λ repressor is present in the cell.  The dimerization of the C-terminus of 
the λ repressor facilitates the N-terminus of the λ repressor binding to the phage operator.  
Importantly for the current work, it has been shown that fusions of unrelated proteins to 
the N-terminus of the λ repressor can confer phage resistance if the fusion partner 
facilitates dimerization of the  λ repressor (129,130). Thus, replacing the C-terminus of 
the  λ repressor with a selected polypeptide chain, allowing the fusion repressor to 
propagate within the host cell, and then infecting with λ phage, allows a simple life-or-
death assay for dimerization. If the bacterial cells survive a challenge with the λ phage 
infection, this indicates that the selected polypeptide chain dimerizes, and confers 
resistance to the phage; if the bacterial cell dies upon challenge with the λ phage, this 
indicates that the selected polypeptide chain is monomeric or does not dimerize the λ 
repressor in a suitable conformation to bind DNA.   
     Randomized libraries of constructs containing chemokine variants were transformed 
into electrocompetent AG1688 E. coli cells, as described in Methods.  In order to obtain 
an accurate count of how many possible colonies were analyzed by the selection process, 
a small portion (1%) of the transformation mixture was separated and plated on LB agar 
plates that did not contain phage.  By counting the number of colonies that appear on the 
non-infected plate, extrapolation of the number of colonies screened on the phage-
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exposed plate was possible.  In this manner, the number of different variants from a 
randomized pool that had been screened could be estimated.  With this high-throughput 
system, it is possible to screen up to 180,000 random variants on one plate.  On average, 
approximately 50,000 mutants can be screened on one phage-coated plate.  In order to 
eliminate false positives, the plasmids from all positives obtained from the selection 
procedure were purified and re-transformed into AG1688 cells, and re-tested using the 
low-throughput cross-streak method.  Only the constructs that allowed cell survival in 
both types of screen were considered true positives and studied further.  
     As controls for the screen, the genes for wild type MIP-1β, MIP-START, wild type 
IL-8 and IL-8-START were placed into the JH391 vector to make a fusion with the N-
terminus of the λ repressor (cI), and transformed into AG1688 E. coli cells.  Three 
constructs performed as expected: cI fusions of MIP-START and IL-8-START (both 
determined to be monomers), showed clear signs of cell death at the phage-bacteria 
interface, and cells containing the IL-8 construct, which should dimerize, showed 
complete vitality.  Wild type MIP-1β-containing cells did not survive despite the fact 
that this chemokine has been shown to form a tight dimer (50).  The orientation of the 
dimer or the lack of stability to proteolysis of MIP-1β in the bacterial cell perhaps 
caused the cell to be susceptible to phage lysis.  Further work on this construct is 
reported below.  Nevertheless, since the IL-8 positive control and both monomeric 
chemokine variants performed as expected (such that at least for the MIP-START-
toward-IL-8 direction the starting and ending points performed as expected), the 
screening procedure proceeded.   
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Randomization with the goal of moving from MIP-1β toward the IL-8 dimer 
     The structure of the IL-8 dimer reveals two major regions of dimer interaction 
(Figure 2-1B).  The most obvious dimer interface region is the antiparallel β−sheet 
formed by the β1 strands of each IL-8 monomer.  In addition, significant dimer contacts 
are made in IL-8 by the C-terminal helix in contact with the 30’s loop of the other 
subunit.   Our work and work by others shows that the IL-8 dimer is at least partially 
retained even with significant changes in the side chains of the β1 strand amino acids, 
indicating a significant component of stability is provided simply by the backbone 
interactions (37,128).  In an attempt to mutate the MIP-1β monomeric variant MIP-
START toward the IL-8-type dimer, MIP-START was mutated at the C-terminus and 
30’s loop region, and also in the β1 strand. The resulting mutants were screened as 
described above. 
     In the 30’s loop region of MIP-START Thr31, Ser32, Pro38 and Ala39 were 
randomly mutated. (Cys35 and surrounding amino acids were not mutated due to the 
structural importance of Cys35 in forming a disulfide bridge.  Pro38 is not part of the 
turn of the loop so this residue was considered structurally safe to mutate.)  A total of 
500,000 colonies were screened, and 3 mutants survived, passing both the high 
throughput screen and the cross streak phage screen (Table 2-1).  However, two of these 
variants were found to contain stop codons in the mutated region.  It has been found that 
some small peptides do allow survival in this selection system without necessarily being  
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Table  2-1: The amino acid sequences of the rational (designed) mutants and the phage system-selected chemokine random 
variants. 
 
MIP-1β WT:      APMGSDPPTACCFSYTARKLPRNFVVDYYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDLELN----     F 
MIP(9):         --------TACCFSYTARKLPRNFVVDYYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDIELN----     F 
MIP(9)-IL8β1:   --------TACCFSYTARKLPRNFVKELRVISS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDIELN----     U 
MIP(9)Y28AV30E: --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDIELN----     F 
MIP-START:      --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFLKRAENS     F 
MIP_1S:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFSKRRENP     F 
MIP_2S:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFTKRNENI     F 
MIP_7S:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFLKRWENK     U 
MIP_8S:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFSKRIENR     F 
MIP_12S:        --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFLKRLENT     F 
MIP_61S:        --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFGKRREN-     U 
MIP_68S:        --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFEKR----     F 
MIP_1G:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFRKRYENS     F 
MIP_4G:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFYKRKENY     F 
MIP_8G:         --------TACCFSYTARKLPRNFVVDAYETSS--LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDFAKRRENV     F 
 
IL-8 WT:        ---SAKELRCQCIKTVSKPFHPKEIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS     F 
IL-8-L25AV27E:  ---SAKELRCQCIKTVSKPFHPKEIKEAREIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS     F 
IL-8-M3:        ---SAKELRCQCIKTVSKPFHPKEIKELRVIESGPHCANEEIIVKLSDGRELCLDPKENWVQRVVEKFLKREENE     F 
IL-8-M5:        ---SAKELRCQCIKTVSKPFHPKEIKEAREIESGPHCANEEIIVKLSDGRELCLDPKENWVQRVVEKFLKREENE     U 
IL-8-T37E-6XC:  ---SAKELRCQCIKTVSKPFHPKEIKELRVIESGPHCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     F 
IL-8-START:     APMGSDPPTCQCFKTYSKPFHPKFIKELRVIESGPHCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     F 
IL-8_A13:       APMGVFHLQCQCFKTYSKPFHPKFIKELRVIEPFGNCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     F 
IL-8_5:         APMGAAPYRCQCFKTYSKPFHPKFIKELRVIEALFICANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_9:         APMGVNRRMCQCFKTYSKPFHPKFIKELRVIEHVLPCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_28:        APMGVSLCHCQCFKTYSKPFHPKFIKELRVIELLFDCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_36:        APMGAEYCRCQCFKTYSKPFHPKFIKELRVIEATIICANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_47:        APMGGQSSRCQCFKTYSKPFHPKFIKELRVIESLLMCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_49:        APMGDVHLYCQCFKTYSKPFHPKFIKELRVIEFYAVCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_63:        APMGSDPPTCQCFKTYSKPFHPKFIKELRVIEVT—-CANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_68:        APMGVVICLCQCFKTYSKPFHPKFIKELRVIETPFPCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
IL-8_86:        APMGARLEGCQCFKTYSKPFHPKFIKELRVIESDCRCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     F 
IL-8_B15:       APMGVPLIFCQCFKTYSKPFHPKFIKELRVIEILYLCANEEIIVKLSDGRELCLDPKENWVQRVVEKFL------     U 
 
β1                              β2                      β3                         α-Helix 
 
The residue numbers for the MIP-1β variants are based on the numbering of wild type MIP-1β; the residue numbers for the IL-8 variants are 
based on the numbers of wild type IL-8.  Residues highlighted by italic are rationally designed mutant residues, while underlined residues 
signify changes selected by the λ repressor system.  Below each alignment is the predicted secondary structure based on the wild type MIP-1β 
and IL-8 structure. F/U in the last column indicates whether the purified proteins studied by NMR are folded (F) or unfolded (U).  There are 8 
folded mutations from MIP-1β mutagenesis screen, and two folded mutations from the IL-8 mutagenesis screen. 
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folded dimeric proteins (131), so these positives were not studied further.  The gene for 
the third positive mutant was subsequently subcloned into an expression vector and 
purified.  However, the NMR spectrum of this protein revealed it to be an unfolded 
protein (Tables 2-1).   
     In the β1 strand region of MIP-START, Asp27, Ala28, Tyr29, Val30 and Thr31 were 
randomly mutated. 400,000 colonies were screened, of which 2 mutants survived the 
phage screening (Table 2-1).  Again, both of these were found to have stop codons in 
this region.  Therefore, none of these truncated proteins were subsequently purified.     
     In terms of selecting for full-length, folded protein, the most successful region of 
mutagenesis in MIP-START was the C-terminal helix (Table 2-1).  In this region amino 
acids Leu66, Ala69 and Ser72 were randomly mutated, as these comprise the appropriate 
face of the helix for making dimer contacts.  730,000 colonies were screened, resulting 
in 11 mutants that survived the phage screens.  One of these was shown to contain a 
frame shift mutation and was not studied further.  The genes for the remaining 10 of 
these mutant chemokines  were placed into an expression vector and subsequently 
purified.  NMR studies indicated that 8 of these were nicely folded, while 2 proteins 
were unfolded (Table 2-1, Table 2-2 and Figure 2-2B).      
Randomization with the goal of moving from IL-8 toward the MIP-1β dimer 
     The MIP-1β  dimer is formed by contacts across the N-terminus and also by contacts 
between the N-terminal amino acids and both the 30’s and the 40’s loop (Figure 2-1A).   
In an attempt to form the CC chemokine MIP-1β-type dimer from IL-8, the 30’s loop 
and the N-terminal regions on IL-8-START were mutated and screened using the high  
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Table 2-2: Results of the λ phage homodimer repressor selection system screen for random 
variants of MIP-1β and IL-8.  MIP-START and IL-8-START are described in the text and 
in Figure 2-2.  
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throughput screening method.  As mentioned, DNA from successful colonies in the high 
throughput screen was further tested with the cross streak method to remove false 
positives.   
     In the 30’s loop region (Ser30, Gly31, Pro32 and His33), a total of 1,200,000 
colonies were screened, of which 2 mutants passed both types of screening procedure.  
One of these genes contained a stop codon in the sequence, so was not studied further.  
Expression of the other gene was unsuccessful after repeated attempts at purification.  
     In the N-terminal region of IL-8-START (Ser2, Asp3, Pro4, Pro5 and Thr6), 470,000 
colonies were screened, of which 3 mutants passed the screen.  Each of these was 
sequenced and shown to contain a stop codon near the beginning of the gene, coding for 
a short peptide (as seen for some of the MIP-START screens).  Therefore, none of these 
were subsequently expressed or purified. 
     Extensive screening was carried out by mutating IL-8-START simultaneously at both 
the N-terminus and the 30’s loop (Ser2, Asp3, Pro4, Pro5, Thr6, Ser30, Gly31, Pro32 
and His33).  It was recognized that both Gly and Pro contribute structurally to the turn in 
IL-8, but since this region makes some of the few non-N-terminal dimer contacts in 
MIP-1β and since this loop in IL-8 is long enough to not require a tight turn, 
mutagenesis proceeded.  2,700,000 colonies were screened, resulting in 11 mutations 
that conferred survival in both types of phage selection.  The genes for these were placed 
into expression vectors and the resulting protein purified.  NMR studies indicated that 
only 2 of these proteins were folded while 9 proteins were unfolded.  Each of these 
proteins was very difficult to work with, requiring multiple preparations and resulting in 
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very poor yields both in protein amounts and in final folded product, suggesting that this 
family of mutants results in generally unstable protein.  
     In total, 6,000,000 colonies were screened, resulting in 16 MIP-1β variants that 
conferred survival to phage, and 16 IL-8 variants that conferred survival to phage.  Of  
these, the genes for 22 were placed into expression vectors, the protein purified, 
resulting in 8 folded MIP-1β mutants and 2 folded IL-8 mutants (Table 2-1, Figure 2-2B, 
Figure 2-2D); see below for analysis). 
Analysis of the purified mutants from the screen of random variants 
     The designed MIP-START and IL-8-START were determined to be monomers by 
AUC (Table 2-3), and NMR was used to compare these starting monomers with the 
random variants.  Nuclear magnetic resonance is a powerful method to investigate the 
structure of proteins and to detect residue-specific changes in structure. The 15N-1H 
HSQC (Heteronuclear Single Quantum Coherence) experiment provides a spectrum 
showing a single peak corresponding to each covalently bonded 15N-1H pair in the 
protein. The chemical shift position of a peak is dependent on the local molecular 
environment and as a result the HSQC spectrum for each protein is unique, providing a 
“fingerprint” of the protein.  
     In order to analyze the positive mutants from the selection, the MIP-1β variants 
described above were purified individually and their spectra were measured.  These 
spectra were overlaid with that of MIP-START to determine the level of change from 
the original monomer starting point.  Figure 2-2B shows the 15N - 1H HSQC spectrum of 
all eight folded variants overlaid with the starting monomer MIP-START.  These  
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Table 2-3: The summary of molecular weight and dimerization state of IL-8 and MIP-1β mutants in this chapter.  
( a: Determined by analytical ultracentrifugation equilibrium experiments; b : Estimated by size exclusion chromatography; c: Estimated by NMR HSQC spectrum comparison 
with known protein; e. Laurence et al. 2000.   * For each mutant, average and standard deviation are calculated from multiple experiments (constant concentration variable speed 
or variable concentration and speed: 50µM IL-8-START,50µM IL-8_A13 and  50µM IL-8_86 run on 26500rpm and 37500rpm; 45µM, 90µM and 180µM MIP-START run on 
16000rpm, 26500rpm and 40000rpm respectively; 30µM MIP_8S and 30µM MIP-68S run on 26500rpm and 37500rpm ;10µM cI-IL-8 WT run on 16000rpm and 26500rpm;10µM 
and 15µM cI-IL-8-START run on 16000rpm and 20000rpm respectively;20µM cI-IL-8_86 run on 16000rpm and 37500rpm;20µM cI-MIP-1β WT run on 16000rpm and 
26500rpm;10µM and 12µM cI-MIP-START run on 16000rpm and 20000rpm respectively;30µM cI-MIP_8S and 20µM cI-MIP_8G run on 16000rpm and 26500rpm respectively. 
Data from each individual experimental are best fit with a single ideal model using Origin program (Beckman Inc.) except IL-8 WT, MIP-1β WT, cI-IL-8 WT and cI-MIP-1β WT 
which are best fit with monomer-dimer association model and are indicated with “Dimer” in the table.   ** Positive or negative  number mean positive or negative 95% 
confidential intervals from the best fitting of  weighted self association monomer-dimer model using Origin program (Beckman Inc.) .        N.D.: Not done    -: Data are not 
consistent with monomer-dimer self association model.) 
 
 
Mutants 
 
Monomer 
molecular 
weight (kDa) 
 
AUC estimated 
molecular weight 
(kDa)* 
 
AUC estimated 
dimer Kd 
(µM)** 
Size exclusion 
chromatography 
estimated molecular 
weight (~kDa) 
 
Conclusion: 
D:  dimer 
M: monomer 
IL-8 WT 
IL-8-L25A_V27E 
IL-8-T37E-6XC 
IL-8-START 
8.36 
8.37 
7.67 
10.3 
Dimer 
Dimer 
N.D. 
10.0±0.6 
0.194 
151.5 
- 
- 
16 
16/8 
8 
10 
Da,b  
Da,b 
Ma,b 
Ma,b,c 
IL-8 _A13 10.0 9.46±1.2 - 10 Ma,b,c 
IL-8 _86 
MIP-1β 
9.95 
7.80  
9.31±0.5 
Dimer 
- 
0.73e 
10 
N.D. 
Ma,b,c 
Da,b,c 
MIP(9)Y28AV30E 
MIP-START 
7.01 
7.51 
N.D. 
8.14±0.5 
- 
- 
N.D. 
8 
                 Mc 
Ma,b,c 
MIP_1G 7.68 N.D. N.D. N.D. Mc 
MIP_4G 7.73 N.D. N.D. N.D. Mc 
MIP_8G 7.61 N.D. N.D. N.D. Mc 
MIP_1S 7.62 N.D. N.D. N.D. Mc 
MIP_8S 7.63 6.59±0.6 - N.D. Ma,c 
MIP_12S 7.61 N.D. N.D. N.D. Mc 
MIP-68S 7.17 10.1±0.4 - N.D. Ma,c 
cI-IL-8 WT 25.5 Dimer 1.0 (-0.4+0.6) 50 Da,b 
cI-IL-8-START 25.2 28.9±2.5 - 25 Ma,b 
cI-IL-8_86 24.8 22.7±6.1 - 25 Ma,b 
cI-MIP-1β WT 24.9 Dimer 13.1(-4.7+3.6) 50 Da,b 
cI-MIP-START 24.7 24.8±0.9 - 25 Ma,b 
cI-MIP_8S 24.8 25.8±0.1 - 25 Ma,b 
cI-MIP_8G 24.7 23.5±4.7 - N.D. Ma 
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random mutants are nicely folded, but the spectra are very similar to known monomer 
MIP-START, indicating a similar structure to the starting material without a major 
quaternary rearrangement. Therefore, a reasonable conclusion is that all selected MIP-1β 
mutants are still monomers.  
     The folded IL-8 mutants described above and in Table 2-1 were purified and their 
“fingerprint” 15N - 1H HSQC spectra were measured and compared to that of IL-8-
START to determine the level of structural change from the starting monomer.  Both IL-
8_A13 and IL-8_86 were clearly folded, and showed some significant spectral variation 
from the starting monomer (Figure 2-2D).  However, these variants were further studied 
by AUC (analytical ultracentrifugation) (Figure 2-3) which showed them to still be 
monomers, not dimers.  Therefore neither of these mutants selected by the repressor 
fusion phage system appears to be a dimer.  
Characterization of the repressor fused chemokines mutants in vitro 
     It was somewhat surprising that the chemokine mutants selected by the repressor 
fusion system appear to be monomers, not dimers, since the selection with cI-fused 
monomers should cause bacteria to die when challenged with phage.  However, studies 
of the expressed and purified random variants were carried out on the chemokines alone, 
free of the fusion partner, while the selection system is based on the ability of the protein 
to dimerize when it is fused with the N-terminus of the λ repressor.  Therefore, the 
positive variants might be dimers when fused to the λ repressor but monomers in the 
absence of the fusion partner.  In order to test this possibility, some of the chemokine 
variants in fusion with the repressor were examined.  Wild type MIP-1β, IL-8, and 
  
49
several of variant chemokines shown in Table 2-1 were expressed and purified as fusions 
with the N-terminus of the λ repressor, creating the same protein that is used in the 
bacterial selection system to allow the cell to avoid phage lysis.  These proteins were 
investigated by size exclusion chromatography and analytical ultracentrifugation in order 
to assess their quaternary state.  
     Both wild type MIP-1β and wild type IL-8, when fused to the N-terminus of the  λ 
repressor, eluted as dimers on a Superdex G75 column (Figure 2-4) and behaved as 
dimers in the analytical ultracentrifuge (Table 2-3), as expected.  In addition, the 
monomeric variants MIP-START and IL-8-START also behaved as expected when 
fused to the N-terminus of the λ repressor, behaving as monomers in analytical 
ultracentrifugation experiments and eluting from the G75 column as monomers (Table 2-
3, Figure 2-4).  However, two representative variants positively selected from the phage 
screen, MIP_8S and IL-8_86, exhibited properties indicative of monomers, not dimers 
when fused to the λ repressor (Figure 2-4, Table 2-3).  This is consistent with  the results 
(described above) of these variants expressed without the λ fusion partner, which also 
revealed fully monomeric protein. These results show that chemokine variants selected 
from the repressor based homodimer system do not appear to be dimers, in the presence 
or absence of fusion partner, at least under the current various in vitro conditions. 
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 Figure 2-4: Size exclusion chromatography of the λ repressor (cI)-fused chemokine 
variants.  The vertical axis represents the absorbance at 280 nm; the horizontal axis 
represents the elution volume (mL) of the samples analyzed. The vertical line denoted “D” 
indicates the elution position of a cI-fused chemokine dimer (MW 50 kDa) while the 
vertical line denoted “M” indicates the position of a cI-fused chemokine monomer (MW 25 
kDa). A) cI fused MIP-1β and variants.  B) cI fused IL-8 and variants.  
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Discussion 
     The twenty natural amino acids provide for a nearly unlimited number of possible 
protein sequences but the total number of protein folds expected to exist is relatively 
small, with many proteins falling into structurally similar families (132).  Clearly, some 
folds are extremely abundant, including the chemokine fold.  Currently there are about 
50 identified chemokines and all determined structures show that these proteins share a 
very similar “chemokine fold” although very different quaternary structures have been 
observed.  Interestingly, CC chemokines that dimerize show a typical MIP-1β type 
dimer and CXC chemokines that dimerize share a typical IL-8 type dimer (25,31).  The 
exceptions to these generalizations are rare and occur in situations where solution studies 
support this trend, while the X-ray crystal structure appears to show atypical quaternary 
structure (17,18,133,134). Regardless, the chemokine monomeric unit can support at 
least two very different dimer types.   
     Recent evidence, including in vivo work, has demonstrated that the chemokine dimer 
is important for function, likely involved in binding cell surface sugars that allow 
localization of the chemokine prior to receptor binding  (9,29,115,116).  However,  
monomeric variants of several chemokines have been shown to be competent to bind and 
activate the cognate chemokine receptor (37-39), indicating that a monomer-dimer 
equilibrium is an important component of chemokine function.  
     In the current work, both structure-based “rational” mutagenesis and random 
mutagenesis were applied to two representative members of the chemokine family of 
proteins in order to investigate the robustness of the chemokine fold and the ability of 
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the chemokine to form an alternate dimer arrangement.  Mutations to MIP-1β 
(representative of the CC subfamily) and to IL-8 (representative of the CXC subfamily), 
based on their known structures, were successful in disrupting the dimer of each protein 
to make a folded monomer.  Others have reported changes to IL-8, particularly in the β1 
strand region, with varying changes to the quaternary structure.  Lowman et al. mutated 
residues 24 and 28 and found little change in the dimer dissociation constant, eventually 
opting to make multiple mutations to disrupt the intersubunit helix contact in order to 
form a monomer (128). More recently, other double mutations in the β1 strand were 
reported to result in monomers (116).  In our hands, mutations to the β1 strand of IL-8 
weakened the dimer, but to make a fully monomeric protein we opted to truncate the C-
terminal α-helix.  For either IL-8 or MIP-1β, further mutation to favor the dimer type of 
the other subfamily generally still resulted in a folded monomer rather than an alternate 
dimer, suggesting that the chemokine fold can be adopted by a wide variety of amino 
acid sequences, although the chemokine dimer is much more sensitive to specific amino 
acid arrangement.   
     A novel use of a λ repressor-based homodimer selection system to investigate 
chemokine dimerization was employed for large-scale dimer selection of randomly 
mutated MIP-1β and IL-8 variants.  This work resulted in more sequence variation in 
monomers, but no dimer forms: the screened “positive” CC chemokine mutants, and, to 
a lesser extent, the CXC mutants, were observed by NMR to be similar to the starting 
monomeric variant.  
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     The lack of success in forming dimers may have several causes.  It is possible that the 
correct region of mutation that would lead to an alternate dimer in either chemokine was 
not chosen, or sufficient numbers of colonies in the selection system were not screened.  
Many of the selected variants were found to be expressed as inclusion bodies and 
refractory to refolding attempts, suggesting that despite tolerating a great deal of 
sequence variation, eventually stability of the protein becomes a problem in the selection.  
In addition, there is the possibility that the use of (human) chemokine fusion partners in 
the (bacterial) selection system did not allow proper folding in the cell and therefore 
compromised the selection process, despite the fact that the control fusion constructs 
were mostly successful upon challenge with phage.  There is also the possibility that the 
chemokine dimer is difficult to form in the presence of a large fusion partner. CC 
chemokines dimerize at their N-terminus, which is also the location of the fusion partner 
in the selection system.  While in theory, there is a long enough linker region to allow 
dimerization to occur, this may be energetically disfavored.  Indeed, investigation of the 
wild type CC chemokine MIP-1β in fusion with the repressor shows a weaker dimer by 
analytical ultracentrifugation than the fusion of repressor with wild type CXC 
chemokine IL-8.  Finally, of course, there is the possibility that no moderate amount of 
sequence variation will allow a switch of chemokine dimer type despite the unique 
characteristics of the family that make alternate dimers seem like a structural possibility. 
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CHAPTER III 
THE HUMAN CC CHEMOKINE MIP-1β DIMER IS NOT  
COMPETENT TO BIND TO THE  CCR5 RECEPTOR* 
 
Introduction 
     Chemokines (chemotactic cytokines) are a group of small (7-14 kDa) structurally 
related proteins that regulate cell trafficking of various types of leukocytes through 
interactions with a subset of seven-transmembrane, G protein-coupled receptors (GPCRs) 
and cell surface glycosaminoglycans (GAGs).  There are two major chemokine 
subfamilies, CC and CXC, named for the placement of conserved Cys residues near the 
N-terminus.  The critical role played by chemokines in recruiting leukocytes and 
inhibiting HIV entry has led to a great deal of interest in their structural biology.  Many 
chemokine structures have been solved, both by NMR and X-ray crystallography 
(12,14,15,17,19,25,32,133,135). These structures reveal that all chemokines share a 
common fold, composed of three β strands in a Greek key arrangement, followed by a 
C-terminal α-helix.  Many chemokines form dimers with affinities generally in the high 
nanomolar or low micromolar range, leading several groups to study the biological role 
of the chemokine quaternary state.  An early study in this area showed that the obligate  
                                                 
 
* Reprinted with permission from “The human CC chemokine MIP-1β dimer is not 
competent to bind to the CCR5 receptor” (139) by Hongjun Jin, Xiaohong Shen, Brandi 
Renee Baggett, Xiangming Kong and Patricia J. LiWang, 2007,  Journal of Biological 
Chemistry, 282 (38), 27976-27983. Copyright © 2007 by the American Society for 
Biochemistry and Molecular Biology. 
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monomer of the CXC chemokine IL-8 did retain activity on neutrophils in vitro (37), and  
later work by our group and others showed that monomeric variants of the CC 
chemokines MIP-1β and MCP-1 were also able to bind and activate their respective 
receptors (38,39). 
     However, a growing body of evidence suggests a biological role for the dimer.  An 
obligate dimer of the CXC chemokine IL-8 was shown to be able to bind its receptor 
(40-42) as was the CC chemokine MCP-1 (38,43) although in the latter case it is not 
clear whether the cross-linked dimers that were reported had a similar dimer structure to 
the wild type protein.  More recently, it was shown that monomeric variants of some 
chemokines were unable to recruit leukocytes in vivo, despite  having receptor activity in 
vitro (9).  Further indication of the role of the chemokine dimer includes studies in 
which GAGs have been shown to mediate chemokine oligomerization (38), including 
playing a direct role in tightening the CC chemokine dimer (29). 
     Despite the accumulation of data regarding the role of quaternary state in chemokine 
function, and the clear evidence that at least some chemokine monomers are competent 
to activate cognate receptors in vitro, no direct evidence has yet been reported on 
whether a CC chemokine dimer can or can not bind to its receptor. In particular, it has 
never been shown definitively if a chemokine dimer is able to bind the CCR5 receptor or 
if the dimer has some role in receptor function, in part because it is not possible to 
observe the quaternary state of a chemokine in standard receptor experiments.  
Chemokine receptors have been shown to dimerize (136,137), leading to the possibility 
that multimerization of chemokine ligand on the receptor could lead to multimerization 
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of the receptor.  This question is particularly intriguing since the two chemokine 
subfamilies have completely different dimer structures, leading to the possibility of 
different results for different subfamilies (138).  In the present study, a covalent dimer of 
the CC chemokine MIP-1β was produced by a single amino acid substitution (MIP-1β-
A10C). This variant was shown to be a non-dissociating dimer that forms a disulfide 
bond at the center of the dimer interface, and its structure is largely the same as the wild 
type protein. It has been determined that MIP-1β-A10C neither binds nor activates the 
MIP-1β receptor, CCR5. However, the receptor activity was recovered upon reduction 
of the intermolecular disulfide bond.  To the best of our knowledge, results reported here 
represent the first direct evidence that the CC chemokine dimer does not bind to its 
receptor and thus offers new implications for chemokine-related drug development.   
 
Experimental Procedures 
Production and purification of MIP-1β variants  
     The genes for MIP-1β-A10C and A10S were produced using the QuikchangeTM 
procedure (Stratagene, La Jolla, CA) in a variant of pET32-Xa/LIC (Novagen, Madison, 
WI). Mutations were confirmed through DNA sequencing. These MIP-1β variants 
protein were produced in E. coli strain BL21(DE3) and purified as follows.  The cells 
were grown in 1 liter of minimal medium containing 15NH4Cl as the sole nitrogen source 
(when preparing protein for NMR assignment experiments, 13C6-glucose was the sole 
carbon source). Protein production was induced by addition of IPTG to 1 mM in 37C 
culture for 7 hours, and the cells were harvested by centrifugation at 6,000 x g in an 
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F10S-6X500y rotor (Piramoon Technologies Inc.) for 30 minutes. The cells were 
resuspended in 30 mL of 500 mM NaCl, 20 mM Tris (pH 8), and 10 mM benzamidine 
and French pressed twice at 16,000 psi. After centrifugation for 30 minutes at 17,000 x g 
in an SS34 rotor (Sorvall Instruments), the pellet was resuspended in 10 mL of 5 M 
guanidinium chloride, 50 mM Tris (pH 8), 50 mM NaCl, 2mM EDTA, and 10 mM β-
mercaptoethanol. The solution was stirred overnight and then centrifuged for 30 minutes 
at 17,000 x g to remove remaining insoluble pellet. To refold the uncut protein, the 
solution was dropped slowly into 100 mL of 50 mM Tris (pH 8), 50 mM NaCl, 2 mM 
EDTA, and 5 mM β-mercaptoethanol. The diluted protein solution was allowed to 
remain at room temperature for 2 h, and then was dialyzed at 4 °C in 20 mM Tris (pH 8) 
to remove guanidine chloride and ΒME.  After dialysis, precipitated matter was removed 
by centrifugation for 30 minutes at 15,000 x g in an F14S-6X250y rotor (Piramoon 
Technologies Inc.) and the protein was purified on a C4 reversed phase chromatography 
column (Vydac, Hesperia, CA), and lyophilized by the Labconco freeze dry system 
(Labconco Corporation).  The C4 column was found to effectively separate protein with 
correctly formed disulfide bonds from protein that was observed to be unfolded, 
presumably due to incorrect disulfide bond formation. To remove the fusion tag, the 
protein powder was solubilized into ~1mL of 20 mM sodium phosphate (pH 2.5) and the 
volume was increased to ~ 40 mL in 20 mM Tris (pH 8), 50mM NaCl, and 2 mM CaCl2.  
Factor Xa (Novagen) was used for the proteolytic cleavage, which typically took 2 
weeks at room temperature.  SDS-PAGE was used to monitor the cutting reaction.  
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Finally, the cut MIP-1β variants were purified over a C4 reversed phase chromatography 
column and lyophilized. 
Non-reducing SDS-PAGE 
     Equal amounts of MIP-1β variant samples (~10 µg) were resuspended in 10 µl of 20 
mM Tris-HCl (pH 8.0) buffer and mixed with 10 µl of 2X loading sample buffer (20mM 
Tris-HCl, pH6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol) with or without 50 
mM β-mercaptoethanol (reducing reagent), boiled, and electrophoresed on an 17% SDS-
PAGE gel.  
Analytical ultracentrifugation (AUC) 
     Sedimentation equilibrium experiments were carried out on a Beckmann XL-A 
analytical ultracentrifuge using  rotor An-60 Ti at 25˚C.  For MIP-1β-A10C under non-
reducing conditions, the speeds used were 25,000, 38,000, and 45,000 rpm.  Samples 
were composed of 10 µM protein in 20 mM pH 2.5 sodium phosphate buffer containing 
150 mM NaCl.  For MIP-1β-A10C under reducing conditions, the protein was dissolved 
into 200 µL of 20 mM pH 2.5 sodium phosphate buffer containing 150 mM NaCl to a 
concentration of 10µM.  The pH was raised to 7.4 by addition of 2 µl of 1 M NaOH, the 
solution was made to 1 mM DTT, and incubated overnight.  Then 2 µL of 50% 
phosphoric acid was added to lower the pH to 2.5 for AUC experiments. The rotor 
speeds for this reduced sample were 25000, 35000 and 45000 rpm.  During each 
experiment, samples were monitored by absorbance at 280 nm. The solvent density (ρ) 
and partial specific volume of the protein ( _ v ) were calculated from the amino acid 
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compositions using the program Sednterp (obtained from the Boston Biomedical 
Research Institute RASMB web site). The data were processed using the program Origin 
(Beckman) for detecting multiple equilibria and estimating the value of the equilibrium 
constants from the absorbance data (39,121).  Each set of experimental data was fit to an 
ideal model or monomer–dimer equilibrium model using a nonlinear least squares fit.  
Selective reduction of MIP-1β-A10C 
     In order to reduce the inter-molecular disulfide bond formed by the substitution of 
Cys for Ala in MIP-1β, the purified MIP-1β-A10C powder was dissolved in 20 mM 
phosphate buffer saline (pH7.4), 1mM DTT (dithiothreitol, Sigma) was added, and the 
solution was incubated at room temperature for 16 hours and then quenched by adding 1 
M phosphoric acid  to lower the pH to 2.5.  Trifluoroacetic acid was added to 0.1%, 
acetonitrile was added to 10% and the reduced protein was purified on a C4 column and 
lyophilized into dried powder.   
NMR spectroscopy  
     All NMR spectra were acquired at 25 °C on a Varian INOVA 600 MHz spectrometers 
using protein samples at ~1 mM concentration in 20mM phosphate, 10mM NaCl buffer 
(pH 2.5). Chemical shifts were referenced to DSS by the method of Wishart et al. (123).   
     Backbone 13C, 15N, 1H assignment of MIP-1β-A10C and reduced MIP-1β-A10C were 
assigned by using the triple resonance experiments HNCACB (139,140), CBCA(CO)NH 
(141) and HBHA(CO)NH (142). Side-chain assignment of  MIP-1β-A10C were 
determined by using C(CO)NH-TOCSY (143,144),HC(CO)NH-TOCSY(145) (in H2O) 
and HCCH-COSY(146) in D2O. Proline assignment was aided by a home-written 
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proline-edited 13C-HSQC experiment. Distance constraints were obtained from 3D 15N 
and 13C-edited NOESY and 4D 13C/13C-edited NOESY(147) experiments with a mixing 
time of 150 ms.  
CCR5-expressing cell lines  
     A CHO-K1 cell line coexpressing CCR5, Gα16, and apoaequorin was a kind gift from 
Dr. Marc Parmentier from the Institute of Interdisciplinary Research of the Free 
University of Brussels (ULB) Medical School, Brussels, Belgium. This cell line was 
described previously (148) and is used for binding and functional assays. Briefly, cells 
were cultured in HAM’s F12 medium supplemented with 10% fetal calf serum 
(Invitrogen Corporation), 100 units/mL penicillin, and 100 µg/mL streptomycin 
(Invitrogen Corporation). Following selection with 400 µg/mL G418 (Invitrogen 
Corporation) for 14 days, the population of mixed cell clones was used in binding and 
functional studies.  
     A TZM-bl HeLa cell line stably expressing large amount of human CCR5 was 
obtained from the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: TZM-bl from Dr. John C Kappes, Dr. Xiaoyuan Wu and Tranzyme 
Inc. The details of this cell line were described previously (149,150).   
Binding assays  
     CHO-K1 cells expressing wild-type CCR5 were collected from plates with Ca2+ and 
Mg2+-free PBS supplemented with 5 mM EDTA, gently pelleted for 2 min at 1000g, and 
resuspended in binding buffer (50 mM Hepes (pH 7.4), 1 mM CaCl2, 5 mM MgCl2, and 
0.5% BSA). Competition binding assays were performed in Minisorb tubes (Nunc), 
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using 0.08 nM  radio-labeled [125I]- MIP-1β (Amersham-Pharmacia Biotech, 2000 
Ci/mmol) as a tracer, variable concentrations of MIP-1β or its mutants, and 40 000 cells 
in a final volume of 0.1 mL. The level of total binding was measured in the absence of 
competitor, and the level of nonspecific binding was measured with a 100-fold excess of 
unlabeled ligand. Samples were incubated for 90 min at 25 °C, and then the bound tracer 
was separated by filtration through GF/B filters presoaked in 0.5% PEEA.  Filters were 
counted for 1 min in the Beckman Coulter Gamma LS 5000TA counter.   
     Binding assays utilizing HeLa cells were carried out in the TZM-bl cell line by fixing 
the cells onto the 24-well culture plate following the protocol mentioned previously 
(151).  Briefly, TZM-bl cells were cultured in 75 cm2 flask in DMEM medium with 10% 
FBS, 100 units of penicillin and 0.1mg/ml of streptomycin until 30% confluency. Then 
the cells are detached and seeded onto 24-well culture plate, at 105 cells per well, 
overnight. The next day, cells were washed twice in cold PBS and then were overlaid 
with 150 µl of the cold binding buffer. Cells were incubated for 2 hrs at 4 ºC with 0.05 
nM 125I-labeled human MIP-1β (Amersham-Pharmacia Biotech) in the presence of 
various concentrations of chemokine mutants. The reactions were stopped by washing 
wells four times with the cold binding buffer plus 0.5 M NaCl. Cells were lysed by the 
addition of 0.5 mL of 1% SDS. Lysates were transferred to a counting vial, and bound 
radioactivity was counted for 1 min in the Beckman Coulter Gamma LS 5000TA counter. 
     All determinations were performed in duplicate and repeated at least three times.  
Binding parameters (IC50) were determined with KaleidaGraph version 3.6 (Synergy 
Software) using nonlinear regression applied to a one-site competition model.  
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Representative data is shown in Figure 3-5A and Figure 3-5B.  The results are reported 
as fitted IC50 mean value ± S.D. nM.)  
Functional assays   
     The functional response of CCR5-expressing cells to chemokines was analyzed by 
measuring the luminescence of aequorin as described previously (152). CHO-K1 cells 
(described above) were collected from plates with Ca2+ and Mg2+-free DMEM 
(Invitrogen) supplemented with 5 mM EDTA, pelleted for 2 min at 1000g, resuspended 
in DMEM at a density of 5×106 cells/mL, and incubated for 2 h in the dark in the 
presence of 5 µM coelenterazine H (Promega). Cells were diluted 5-fold before being 
used. Agonists in 50 µL of DMEM were added to 50 µL of a cell suspension (50,000 
cells), and luminescence was measured for 30 seconds in an Orion II microplate 
luminometer (Berthold Techniques, Germany). Determinations were performed in 
triplicate, and repeated at least three times.  The receptor activation EC50 were 
determined with KaleidaGraph using nonlinear regression applied to a one-site ligand 
binding model. Representative data is shown in Figure 3-5A. The results are reported as 
fitted EC50 mean value ±S.D. nM.  
Heparin sepharose chromatography of GAG binding studies 
     GAG binding capacity of chemokine mutants were studied by using the heparin 
Sepharose chromatography as mentioned in previous publications (153,154).  Briefly, 
equal amounts of MIP-1β-A10C, MIP(9), MIP-1β-F13L and MIP-1β-L34W 
(approximately 10µg of lyophilized protein) was taken up in 0.5 mL of 50mM Tris 
(pH7.4) and injected onto a 1 mL Hi-Trap heparin column (Pharmacia) using the AKTA 
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FPLC system (GE Healthcare). The column was equilibrated with 5mL of the same 
buffer followed by a gradient of 0 to 1.0 M NaCl in 50 mM Tris (pH7.4) at a rate of 0.5 
mL/min for 60 min. The elution profile was monitored by UV absorbance at 280nm. The 
salt concentration corresponding to the center of each eluted peak is a relative 
determinant of the GAG binding ability of that mutant.  
 
Results 
MIP-1β-A10C is  a covalent non-dissociating dimer 
     In order to obtain an obligate MIP-1β dimer, a single substitution from Ala to Cys at 
the 10th position, which is in the center of dimer interface, was made (Figure 3-1A).  To 
determine the oligomerization state of MIP-1β-A10C, SDS-PAGE experiments were 
carried out.  In the presence of reducing reagent β-mercaptoethanol, MIP-1β-A10C 
migrates nearly identically to wild type MIP-1β on the gel.  In the absence of β-
mercaptoethanol, MIP-1β-A10C migrates more slowly than the wild type MIP-1β 
(Figure 3-1B) at a position indicative of a covalent dimer. To further confirm this, we 
carried out analytical ultracentrifugation equilibrium experiments on the purified protein.  
The ultracentrifugation data did not fit to either a dissociating dimer model or to a 
monomer model, but rather the best fit of the data was to a single species of 15.5 kDa 
(twice the size of the calculated the monomer molecular weight), indicating MIP-1β-
A10C is indeed a non-dissociating covalent dimer (Figure 3-1C). 
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Figure  3-1:  MIP-1β-A10C is a covalent dimer.  A). The ribbon diagram of the homodimer 
structure of MIP-1β (PDB code: 1hum).  Ala10 (red sphere) is in the center of the dimer 
interface. B). Results of non-reducing and reducing 17% SDS-PAGE. Lanes from left to 
right: molecular weight marker (units in kDa), MIP-1β-A10C without BME (β-
mercaptoethanol); MIP-1β-A10C with BME; MIP-1β WT without BME; MIP-1β WT with 
BME; MIP-1β -A10S without BME; MIP-1β-A10S with BME. Only the sample MIP-1β-
A10C without BME shows a molecular weight (~16 kDa) approximately twice that of the 
other samples (~8 kDa) indicating MIP-1β-A10C is a covalent dimer. C). Analytical 
ultracentrifugation equilibrium experiments show that MIP-1β-A10C behaves as a single 
species having the size of a MIP-1β dimer.  
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Figure  3-2:  MIP-1β-A10C has a nearly identical structure to wild type MIP-1β. 13C Cα 
(filled circles) and Cβ (open circles) chemical shift plot of wild type MIP-1β versus MIP-1β-
A10C.  The chemical shift values of  13Cα and 13 Cβ for most residues between the two 
proteins are essentially identical except at the site of mutation (Ala10 on MIP-1β, Cys10 on 
MIP-1β-A10C).  
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MIP-1β-A10C is similar in structure to the wild type MIP-1β dimer 
     The A10C mutation results in three contiguous cysteines (Cys10, Cys11, Cys12), 
each of which must form a correct disulfide bond to result in correctly folded protein.  
While Cys 10 is involved in an intermolecular crosslink, Cys11 and Cys12 form internal 
disulfide links (to Cys35 and Cys51 respectively) as a critical component of the wild 
type tertiary structure.  A detailed NMR investigation was carried out to determine 
whether the structure of the covalent dimer MIP-1β-A10C is identical to that of the wild 
type MIP-1β dimer.  Complete backbone (15N, 1HN, 13Cα, 13Cβ) chemical shifts were 
determined for MIP-1β-A10C, and compared to the wild type values.  13Cα and 13Cβ 
chemical shifts are sensitive to secondary structure and overall fold of the protein, and 
Figure 3-2 shows that these values are essentially identical between the two proteins 
except at the site of mutation.  This indicates that the A10C variant has a typical 
chemokine fold that is likely very similar to wild type MIP-1β.  Further, these data in 
addition to intramolecular NOE distance contacts (data not shown) indicate that the 
native disulfide bonds (Cys11-Cys35, Cys12-Cys51) have not been perturbed. 
     To determine if the interaction of the two monomeric subunits in MIP-1β-A10C is 
the same as in the wild type dimer, we carried out 3D 15N and 13C-edited NOESY and 
4D 13C/13C-edited NOESY experiments on MIP-1β-A10C.  These data (Figure 3-3) 
show that the MIP-1β-A10C dimer makes almost all of the same inter-subunit contacts 
as  the wild type dimer,  including  contacts between G4,  S5,  D6, and P7 to V50’; D6 to  
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Figure 3-3:  MIP-1β-A10C has identical dimer contacts as MIP-1β WT.  A). Ribbon 
diagram of the wild type MIP-1β dimer structure shows the dimer interface and an 
enlarged picture  close to the critical residue Phe13 (14). B). Selected slice from the 4D 13C-
edited NOESY of MIP-1β-A10C showing that this variant has wild type dimer 
intermolecular contacts.  The intermolecular NOE peaks of MIP-1β-A10C indicate that Hδ 
of residue Phe13  makes contact across the dimer with Hβ and Hγ of Thr9’ and Hδ of 
Leu34’ in the structure of MIP-1β-A10C. 
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Figure 3-4:   Selected dimer contacts that were observed in MIP-1β-A10C by 3D NOESY 
spectra. 
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C51’; P8, T9 to C12’; P8 to V41’; and numerous contacts (Figure 3-4) between Phe13 
and T9’ and Leu34’, which can only be made across the dimer and not intra-molecularly 
(Table 3-1).  Not every contact reported for the wild type dimer was able to be 
distinguished for MIP-1β-A10C, although in many cases NOE peaks may be present but 
were too overlapped or low intensity to be assigned unambiguously.  For example, the 
description of the wild type MIP-1β dimer mentions contact between S47’ and both G2 
and S5 (14), but due to extensive overlap we could not unambiguously assign an NOE 
peak for these contacts.  In addition, a few contacts are present in MIP-1β-A10C that 
indicate closer intersubunit contacts for certain atoms than were seen in the wild type 
dimer structure, including NOE contact between S5 and T16’ Hγ, and between F13 Hα 
(as opposed to the side chain) and L34’.  This could indicate an altered structure 
compared to the wild type protein or could be explained by spin diffusion during the 
NMR experiment.  However, overall the structural results suggest that MIP-1β-A10C is 
nearly identical in structure to the wild type dimer, and so our functional results do 
indeed reflect the function of the chemokine dimer, and are not an artifact of altered 
conformation.  
The MIP-1β-A10C dimer is not active on the receptor CCR5  
     Two measures of chemokine receptor function are typically carried out:  activity 
assays and binding assays. The activity assays generally measure the release of 
intracellular calcium stores after productive engagement of the chemokine receptor by its 
ligand.  Binding assays measure the level of chemokine binding to the receptor, 
regardless of  whether an intracellular signal is able to be transmitted.   To  measure  the   
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Table 3-1:  Intermolecular NOE contacts observed for MIP-1β-A10C. 
 
MIP-1β WT dimer 
contact 
 
MIP-1βA10C intermolecular NOESY peaks 
K48 G4Ha-K48’Hd G4 
V50 G4Ha-V50’Hg 
S5 T16’ S5Hb-T16’Hg2 
 V50’ S5Ha-V50’Hg (both methyls) 
S5Hb-V50’Hg (both) 
D6 T16’ D6Hb-T16’Ha, Hb, Hg2 
 V50’ D6Ha-V50’Hg 
D6Hb-V50’Hg (both) 
 C51’ D6Hb-C51’Hb 
P7 V41’ P7Ha-V41’Hg 
 Q49’ P7Ha-Q49’Hb 
P7Ha-Q49’Ha 
 V50’ P7Ha-V50’Ha 
P7Ha-V50’Hg (both) 
P8 C12’ P8Ha-C12’Ha 
P8Hb-C12’Ha,Hb 
 T31’ P8Hb-T31’Ha 
P8Hb-T31’Hg2 
P8Hd-T31’Ha 
 V41’ P8Ha-V41’Hg (both) 
P8Hb-V41’Hg(both) 
P8Hd-V41’Hg(both) 
T9 F13’ T9Ha-F13’Hd 
T9Hb-F13’Hd 
T9Hg2-F13’Ha 
T9Hg2-F13’Hd 
F13 T9’ F13Hd-T9’Ha,Hb,Hg2 
 L34’ F13Ha-L34’Hd (both) 
F13Hb-L34’Hd (both) 
F13Hd-L34’Hd (both) 
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Figure 3-5: MIP-1β-A10C does not bind CCR5. A). CCR5 activity assays using CHO-K1 
cells that stably express CCR5 on their surface. MIP-1β-A10C elicits no activity (open 
circles) until it is incubated overnight with 1mM DTT (filled circles) at which point 
EC50=179±28 nM. Wild type MIP-1β in the presence (filled triangles) of 1mM DTT is 
moderately less active (76±16 nM) than wild type MIP-1β in the absence of DTT (open 
triangles; 11±2.6 nM).  The variant MIP-1β-A10S (open squares) is nearly active as wild 
type MIP-1β (18±2.9 nM). B). CCR5 binding assay, using the same CHO-K1 cells with 125I 
labeled MIP-1β as a tracer. MIP-1β-A10C does not show any significant binding to CCR5 
even at micromolar concentrations (open circles). Wild type MIP-1β (open triangles) yields 
an IC50 = 1.5±0.6 nM and MIP-1β-A10S (open squares) yields an IC50 = 2.1±0.6 nM.  
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ability of MIP-1β-A10C to activate the CCR5 receptor,  activity assays were carried out 
on CHO-K1 cells bearing human CCR5.  As shown in Figure 3-5A, MIP-1β-A10C is 
unable to elicit a response even at micromolar concentrations.  Similarly, binding assays 
reveal that MIP-1β-A10C is unable to bind CCR5 (Figure 3-5B).  To demonstrate that 
mutation to the 10th position is functionally tolerated and that the lack of activity in the 
A10C variant is due to the obligate dimer, the Ala10Ser mutation was made in MIP-1β.  
This variant was shown to be nearly fully active, as expected (Figure 3-5A, 3-5B).  Since 
NMR analysis indicates that the obligate MIP-1β-A10C dimer has the same structure as 
wild type MIP-1β, our data suggest that the lack of ability to bind CCR5 is indeed 
because of the quaternary state of the molecule (i.e. the dimer) rather than due to any 
disruption caused by an amino acid change at the 10th position.   
Partial rescue of receptor activity by selective reduction of the intermolecular disulfide 
bond 
     To demonstrate that the dimer form of the chemokine is responsible for the loss of 
activity, MIP-1β-A10C was incubated in mild reducing conditions (1 mM DTT) to 
reduce the intermolecular disulfide bond, breaking the covalent bond between the 
monomeric subunits. Figure 3-5 shows that some activity on CCR5 is observed for the 
reduced mutant.  
     To demonstrate that mild treatment with DTT does indeed break the disulfide bond of 
the covalent dimer, analytical ultracentrifugation was carried out  on MIP-1β-A10C in 
the presence of DTT.  Under these conditions the best fit to the data was to a dissociating 
dimer with a Kd of 2.7µM, indicating that the covalent link had successfully been 
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reduced (data not showing). To eliminate the possibility that this treatment may also 
reduce the internal disulfide bonds of the protein, NMR experiments were carried out on 
the MIP-1β-A10C variant after treatment with DTT to determine whether these 
conditions disrupted the structure of the mutant.  Carbon chemical shifts are not only 
powerful indicators of protein conformation, but have been shown to be diagnostic of the 
participation of cysteine in a disulfide bond (155). The chemical shift assignments for 
the backbone atoms of MIP-1β-A10C and reduced MIP-1β-A10C were obtained using a 
series of three-dimensional experiments (139,141) with 13C, 15N labeled protein.   The 
chemical shift values of 13Cβ for Cys10, Cys11, Cys12, Cys35 and Cys51 for MIP-1β-
A10C under oxidizing conditions were consistent with a fully disulfide crosslinked 
species, while under mild reducing conditions (1 mM DTT), the chemical shifts of MIP-
1β-A10C were consistent with a reduced Cys 10, and oxidized Cys11, Cys12, Cys35 and 
Cys51 (Figure 3-6).  This strongly indicates that under the mild reducing conditions used, 
the intermolecular crosslink is reduced, while the overall structure of the protein is intact 
and still contains the wild type disulfide bonds.  Overall then, the results show that the 
rescue of activity upon reduction is due to the breaking of the dimer into monomeric 
units that are structurally intact.  Therefore, the intermolecular disulfide bond of MIP-
1β-A10C, and not any structural rearrangement, is the cause of the lack of receptor 
activity for the covalent dimer form of the mutant. 
     Since only a moderate level of rescue was observed for the MIP-1β-A10C variant in 
the presence of DTT, it is possible that variation in the 10th position does affect CCR5  
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Figure 3-6: Only Cys10 is reduced in 1 mM DTT.  The 13Cβ chemical shift values of Cys 
residues were obtained from standard assignment spectra on samples both in the presence 
and absence of 1 mM DTT. As reported by Sharma et al (155), if the chemical shift value 
13Cβ  of Cys residue is above about 33 ppm (cutoff line shown), the Cys is oxidized; if the 
chemical shift value is below the cutoff line, the Cys is reduced.  NMR data collected from 
MIP-1β-A10C (black bar) and MIP-1β-A10C+1mM DTT (white bar) indicated that the 
mutated residue Cys10 is oxidized (along with the other four Cys residues).  With 1 mM 
DTT, only the mutated residue Cys10 is reduced.  
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activity of MIP-1β, or it is possible that DTT negatively affects the outcome of the 
activity assay.  Therefore, activity assays with wild type MIP-1β in the presence of DTT 
were also carried out, and showed a reduced activity for the wild type protein (Figure 3-
5A, 3-5B).  Since the above NMR data suggest that the structure of the chemokine 
remains intact in the presence of the reducing reagent, these experiments suggest that the 
presence of DTT is harmful to the CHO cells, even in the brief period of an activity 
assay.  Results were more dramatic for binding assays in the presence of DTT, where the 
several hours required for the experiment resulted in visibly unhealthy cells and poor 
results.  Therefore, binding results were not able to be obtained for the MIP-1β-A10C 
variant in the presence of DTT on CHO cells.  Binding experiments on CCR5-
expressing TZM-bl HeLa cells consistently suggested that reduced MIP-1β -A10C could 
compete for CCR5 binding, but again the date were very poor, possibly due to the 
presence of DTT, even though the cells appeared healthy (data not shown).  
The covalent MIP-1β-A10C dimer retains glycosaminoglycan binding ability 
     Heparin Sepharose chromatography is a well-established technique used to assess the 
ability of a protein to bind to physiological glycosaminoglycans (GAGs) (153,154).  
Several chemokine mutants of varying quaternary state, including the  monomeric 
variant MIP(9)(50), the weak dimers F13L(39) and L34W(29), and the covalent dimer 
MIP-1β-A10C, were tested for their ability to bind to a heparin sulfate column under 
identical conditions.  Elution was carried out with a sodium chloride gradient.  While 
monomeric variant MIP(9) and weakly dimerizing variants F13L, L34W elute earlier   
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Figure 3-7:  Heparin sepharose chromatography of several dimerization variants of MIP-
1β. Equal amounts of MIP-1β-A10C, MIP(9), MIP-1β-F13L and MIP-1β-L34W were 
loaded onto a heparin sepharose column and eluted using NaCl gradients. The vertical line 
denoted with “D” indicates the elution position of the MIP-1β wild type dimer. The vertical 
line denoted with “M” indicates the elution position of wholly monomeric variant MIP(9).  
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than the wild type protein, the covalent dimer MIP-1β-A10C required at least as much 
salt as the wild type protein to elute from the column (Figure 3-7) indicating that the 
dimer form of the protein is competent to bind GAGs even though it has no receptor 
binding capacity.   
 
Discussion 
     Structural studies show that many chemokines form dimers, and biophysical 
investigations have revealed that the dimer dissociation constant of chemokines is 
generally in the low micromolar range (25).  While this dimer affinity suggests a 
predominant monomeric form of the protein at the nanomolar concentrations presumed 
to be present biologically, numerous studies have shown that the dimer Kd is very 
sensitive to solution conditions, so it is possible that dimers are present in significant 
concentrations in vivo (128,156).  In support of the chemokine dimer as a biologically 
functional entity, it has been shown that chemokines mutated to remove the ability to 
dimerize do not function in vivo, despite these variants having the ability to bind and 
activate their cognate receptor in vitro (9). Overall, although a great deal has been 
reported about the receptor function of chemokine variants (39,47,128), little evidence 
has been accumulated regarding the specific role of the dimer in receptor binding or 
activation, because it is difficult to determine which protein species is actually making 
contact with the receptor:  A “monomeric” variant may actually dimerize on the receptor, 
or, alternately, even a high affinity chemokine dimer may dissociate before binding the 
receptor.     
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     The only way to definitively test the affinity of a dimer for the chemokine receptor is 
to covalently join two monomeric subunits in a way that maintains the structure of the 
wild type dimer.  This has been reported for the CXC chemokine IL-8, where several 
strategies have been utilized to make a covalent dimer (40-42,157). In general, it was 
found that a covalent IL-8 dimer was able to bind both  receptors CXCR1 and CXCR2, 
but with lower affinity than the wild type protein.  Further work with peptides derived 
from the receptor CXCR1 indicate that the IL-8 monomer is the high affinity ligand for 
the receptor (41,158).  However, the CXC chemokine dimer has a completely different 
structure than the CC chemokine dimer and has many receptor binding residues still on 
the surface of the protein.  In contrast, the CC chemokine dimer buries residues that have 
been shown to be critical for receptor binding (39,47,159).  This suggests that a receptor-
bound CC dimer would make different contacts than a receptor bound CC chemokine 
monomer.  Therefore, we have designed a trapped dimer of MIP-1β by replacing Ala10 
at the center of the dimer interface with Cys, forming a disulfide bond between two 
monomeric subunits (Figure 3-1A).  This protein is demonstrably a non-dissociating 
dimer, and shows almost all of the intermolecular interactions typical of the MIP-1β 
dimer.  Assays of both CCR5 binding and CCR5 activity reveal that this covalent dimer 
is not competent to bind its receptor (Figure 3-5A and 3-5B).  Therefore, we conclude 
that the MIP-1β dimer is not competent to bind or activate its receptor, and that this 
conclusion is very likely to be general for the CC chemokine subfamily.   
     What then is the biological role of the CC chemokine dimer?  Evidence has 
accumulated that the ability of chemokines to bind cell surface glycosaminoglycans 
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(GAGs) is linked to the chemokine quaternary state.  Some years ago it was shown that 
GAG binding causes aggregation of both CC and CXC chemokines (160).  In more 
recent studies, it was demonstrated that the monomeric form of MIP-1β has a lower 
affinity for a variety of GAG disaccharides than the wild type (dimer) form (115).  
Further, the binding of GAGs by MIP-1β was shown to increase the chemokine dimer 
affinity (29). Similarly, the CXC chemokine SDF-1 was shown to dimerize with higher 
affinity under in the presence of several solutes, including GAGs (156).  Although GAG-
induced oligomerization may be a mechanism to reduce chemokine activity, the GAG 
binding surface and receptor binding surface of MIP-1β do overlap so lesser activity of 
chemokines in the presence of GAGs may also be a function of competition between 
GAG and receptor for chemokine binding (47). 
     These data support a model of chemokine action in which the chemokine is 
immobilized on the endothelial surface in the dimeric (or higher order oligomeric) form 
by binding to cell surface GAGs. The ability to dimerize is likely critical for GAG 
affinity, for chemokine gradient formation, or for the ability of the chemokine to be 
presented appropriately to the receptor on the surface of a chemotaxing leukocyte that is 
passing nearby.  Dissociation of the chemokine oligomer into monomeric subunits likely 
occurs as part of the process of transferring the chemokine from the GAG to the receptor.  
This dissociation from the dimer (or oligomer) form to the monomer form is evidently 
necessary in order to bind and activate the cognate receptor, at least in the case of CC 
chemokines, as shown by the present work on the CC chemokine MIP-1β.  
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CHAPTER IV 
BIOPHYSICAL STUDIES OF POTENT ANTI-HIV CHEMOKINE MUTANT 
PROTEIN P2-RANTES  
 
Introduction 
     Chemokines bind to seven transmembrane-spanning G-protein-coupled receptors 
(GPCRs) and mediate leukocyte migration involved in a wide range of physiological 
phenomena including immunodefense, inflammatory, nerve cell derivation, would 
healing, cardiac angiogenesis, cancer development and are involved in blocking HIV 
infection (1,3,25,161,162). The CC chemokine, CCL5/RANTES (Regulated upon 
Activation Normal T cell Expressed and Secreted) can bind and activate receptors CCR1, 
CCR3, CCR4 and CCR5 (1,3,25). RANTES can mediate chemotaxis and activation of 
macrophages (or monocytes), eosinophils, basophils and T cells (162,163). Increased 
RANTES expression is related to a wide range of inflammatory disorders and 
pathologies (3,162,164). RANTES also inhibits HIV-1 entry and infection by competing 
with the virus for CCR5 binding (1,76,80,165).  
     It has been shown that the N-termini of RANTES are critical for receptor binding and 
activation. Alanine scanning mutagenesis revealed that the N-loop region is the 
determinant for binding the receptor and the N-terminal region is for receptor activation 
(46). For example, it has been found that Arg17 is necessary for RANTES binding to 
CCR1, Phe12 for binding to CCR3, and Pro2, Phe12 and Ile15 for binding to CCR5. 
Pro2, Asp6, Thr7 near the N-terminus are involved in activating CCR1; Pro2 and Try3 
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for CCR3; and Try3 and Asp6 for CCR5 (46). Several N-terminal truncated derivatives, 
extended mutants and N-termini modification mutants of RANTES have been produced 
by selection or recombinant methods and exhibit antagonist or partial agonist functions. 
For example, N-terminal peptide fragments RANTES(1-14) (166), RANTES (3-
68)(167), RANTES (4-68)(168), RANTES (8-68) (169),  RANTES (9-68) (81,169) and 
RANTES (10-68) (169) truncated mutants were reported to be antagonists in CCR5 
binding and block HIV fusion. Met-RANTES and Leu-RANTES are mutants that are 
extended at the N-terminus by nature amino acids. They are found to be partial agonists 
(90,97,170-173). Subsequently, a range of N-terminal artificial chemical modification 
derivatives of RANTES were widely reported, for example, AOP-RANTES (174), 
NNY-RANTES(175), PSC-RANTES (93,168,176,177).          
     Recently, towards improving the function of blocking the HIV entry property of 
RANTES, a phage display techniques was applied to select RANTES mutants against 
living cell expressing CCR5 (100). From this work, came potent anti-HIV mutant, 
named P2, which has a modified N-terminal sequence: FSPLSSQSS-RANTES (9-68) 
(100) (Figure 1-7). The chemically synthesized polypeptide of P2-RANTES has been 
shown by Hartley et al. to only selectively activate CCR5, not CCR1 or CCR3 in 
calcium release signal transduction experiments. It shows improved binding affinity to 
CCR5 in competition radioactive assays. In env-mediated cell-cell fusion assays and 
PBMC HIV-1 infection assays, P2-RANTES resembles AOP-RANTES function 
because of its tight binding affinity and strong CCR5 down modulation function (100). 
In order to investigate the structural basis of this unique mutant, we produced this mutant 
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using the E. coli overexpression and refolding techniques and solved the structure by X-
ray crystallography. Our AUC studies show P2-RANTES is a monomer in solution, but 
the crystal structure of P2-RANTES shows it is a unique tetramer. The N-terminal 
extended residue, Phe0, plays an important role in the oligomerzation and packing. The 
first 9 residues on the N-terminus of P2-RANTES in the subunit A and B are clearly 
defined due to the oligomerization restraints. In particular the first 3 residues are well 
defined while these residues on the x-ray structure of wild type RANTES are not defined 
(15,16,178). These structural studies reveal the structural basis of activity of the unique 
variant.  These findings may lead to further design of potent anti-HIV entry inhibitors.  
This structural work may also be therapeutically useful to further design antagonists for 
CCR1 and CCR3 in the future.  
 
Experimental Procedures 
Chemicals and reagents 
     All cell culture media, supplements, and sera were purchased from Invitrogen 
(Carlsbad, CA). Fusion inhibitor (N-acetylated derivative), T-20 (catalog No: 9845) was 
obtained from the NIH AIDS Research and Reference Reagent Program through Roche. 
Mouse monoclonal antibody to human CCR5 was obtained through the NIH AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAD, NIH:  mouse anti 
human CCR5 monoclonal antibody from R&D system (catalog number: FABSP1, clone: 
45502). FITC (fluorescein isothiocyanate) labeled F(ab')2 fragment of polyclonal goat 
anti-mouse IgG second antibody was purchased from Sigma (catalog number: F 2653). 
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Cell culture and cell lines 
     HeLa cell line stably expressing HIV-1 ADA (R5) env (referred to as HeLa-ADA) 
was a kind gift from Dr. M. Alizon (Cochin Institute, Paris, France) (179). Cells were 
cultured in DMEM supplemented with 10 % FBS, and 100 units of penicillin and 0.1 
mg/ml of streptomycin and the ADA (R5) env was selectively expressed by adding 2 
µM methotrexate (Sigma) as previously published (180). A HeLa cell line stably 
expressing human receptor CD4 and CCR5 (referred to as HeLa-P5L) was a kind gift 
from Dr. M. Alizon (Cochin Institute, Paris, France) (179). Cells were cultured in RPMI-
1640 (Invitrogen) supplemented with 10 % FBS, and 100 units of penicillin and 0.1 
mg/ml streptomycin. The expression of CCR5 was selected by adding zeocin (Invitrogen) 
0.5 mg/ml. A HeLa-TZM cell line was obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from Dr. John C. 
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.(181). The cells were cultured at DMEM 
supplemented with 10% FBS, 100 units of penicillin and 0.1 mg/ml of streptomycin as 
mentioned in the instruction. 3T3 cell are cultured in DMEM supplanted with 10% FCS 
with 100 units of penicillin and 0.1 mg/ml streptomycin. 
Protein expression and purification 
     The wild type RANTES was purified as shown previously (115). For the RANTES 
mutant, P2-RANTES, its corresponding gene (100) with an upstream Factor Xa cut site 
was amplified using PCR with the wild type RANTES as a template. The PCR product 
of P2-RANTES was ligated into  pET32-Xa (Novagen) at the Nde I-BamH I sites, and 
the DNA sequence of this mutant was confirmed through DNA sequencing. Protein 
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production was induced by addition of IPTG to 1 mM in 37ºC culture of BL21(DE3) 
(Novagen) bearing the constructed plasmids for 7 hours, and the cells were harvested by 
centrifugation at 6,000 x g in an F10S-6X500y rotor (Piramoon Technologies Inc.) for 
30 minutes. The cells were resuspended in 30 mL of 500 mM NaCl, 20 mM Tris (pH 8), 
and 10 mM benzamidine and French pressed twice at 16,000 psi. After centrifugation for 
30 minutes at 17,000 x g in an SS34 rotor (Sorvall Instruments), the pellet was 
resuspended in 20 mL of 5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl.  
The solution was stirred overnight and then centrifuged for 30 minutes at 17,000 x g to 
remove the remaining insoluble pellet. The soluble denatured proteins were loaded onto 
a 5ml Ni-chelating column (Amersham Pharmacia Biotech) equilibrated with same 
buffer (5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl).  The denatured 
proteins were purified through the Ni-chelating column using a gradient from 10% to 
100% of 500 mM imidazole in 5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM 
NaCl. The fractions containing purified denatured protein were pooled together and 
slowly shaked (~50 rpm) for 2 hours in room temperature after adding 10mM β-
mercaptoethanol. The purified denatured proteins were dialyzed against 20mM Tris-HCl, 
pH8.0 buffer overnight at 4ºC.  After dialysis, precipitated matter was removed by 
centrifugation for 30 minutes at 15,000 x g in an F14S-6X250y rotor (Piramoon 
Technologies Inc.) and the protein was purified on a C4 reversed phase chromatography 
column (Vydac, Hesperia, CA), and lyophilized by the Labconco freeze dry system 
(Labconco Corporation).  To remove the fusion tag, the protein powder was solubilized  
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Figure 4-1: Characterization of purified P2-RANTES on MALDI-TOF Mass spectrum. 
There are two main peaks shown in the spectrum. The left peak is the double charged peak 
(molecular weight /charge= 3946.1) and right peak is the single charged peak (molecular 
weight /charge = 7893.8). The observed molecular weight of P2-RANTES from this 
experiment is 7894 ± 8 Da. The calculated molecular weight from the amino acid 
composition (using average isotope composition) is 7906 Da.    
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into ~1mL of 20 mM sodium phosphate (pH 2.5) and the volume was increased to ~ 40 
mL in 20 mM Tris (pH 8), 50mM NaCl, and 2 mM CaCl2.  Factor Xa (Novagen) was 
used for the proteolytic cleavage, which typically took 2 weeks at room temperature.  
SDS-PAGE was used to monitor the cutting reaction.  Finally, the cut proteins were 
purified over a C4 reversed phase chromatography column and lyophilized into powder. 
MALDI-TOF mass spectroscopy 
       The lyophilized powder of P2-RANTES sample was dissolved in 100 µl of 0.1% 
TFA and mixed 1:1 with a-Cyano-4-hydroxycinnamic (6 mg/ml solution in 50% 
acetonitrile, 0.05% TFA).  The MALDI-TOF mass spectra of the samples were acquired 
using a Shimadzu Kratos Axima-CFR mass spectrometer equipped with a pulsed 
nitrogen laser emitting at 337 nm (Shimadzu Biotech).  All spectra were acquired in the 
positive ion mode using 20 kV acceleration voltage.  The spectrum is the average of 400 
laser pulses and was analyzed with Kompact Software Version 2.4.1 by Shimadzu 
Biotech. Calibration was performed using the doubly and singly charged ions of 
cytochrome C (Figure 4-1). 
 Structural determination and refinement 
        The structure of P2-RANTES was determined by molecular replacement using the 
structural model of AOP-RANTES (PDB id: 1B3A) as search model. The first ten 
residues were deleted from the search model. Four molecules of the search model were 
located in the unit cell using the program MOLREP in the CCP4 suit (182). The solution 
 was improved by rigid body refinement using CNS (183). The electron density map  
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Table 4-1: Data collection and refinement statistics. 
 P2-RANTES 
Data collection  
Space group C2 
 
Cell dimensions  
 a, b, c (Å) 116.68, 51.98, 61.69 
 α, β, γ (°) 90, 117.87, 90.0 
Resolution (Å) 50–1.70 (1.76-1.70) 
Rmerge 4.6 (19.9) 
I / σI 49.9 (6.5) 
Completeness (%) 97.4 (79.6) 
Redundancy 3.4 (2.5) 
  
Refinement  
Resolution (Å) 50–1.70 
No. reflections 34,463 
Rwork / Rfree 21.7 / 24.8 
 
No. atoms  
 Protein 2,123 
 Water 313 
 
B-factors  
 Protein 36.0 
  
 Water 50.4 
 
R.m.s. deviations  
 Bond lengths (Å) 0.010 
 Bond angles (°) 1.56 
 
Data were collected from a single crystal for each structure. Values in parentheses are for 
highest-resolution shell. This work was done in collaboration with Dr. Pingwei Li. 
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calculated from the model after rigid body refinement showed clear and complete 
electron density for the first 10 residues for one of the mutant molecule and fragmented 
density for another molecule. No electron density was observed for the first 9 residues of 
the other two molecules in the asymmetric unit, which are supposed to be disordered. 
The molecular model was completely rebuilt for the first ten residues of molecule A and 
B according to 2|Fo|-|Fc| simulated annealing omit map. The model was refined by 
several cycles of positional refinement and remodeling. In the final stage of the 
refinement, individual B factors were refined and solvent molecules were added to peaks 
higher than 3σ in the difference map. The crystallographic R factor for the final model is 
21.7% and Rfree is 24.8%, with good geometry. Statistics of the crystallographic data and 
refinement is listed in Table 4-1. 
Analytical ultracentrifugation 
       Sedimentation equilibrium and sedimentation velocity measurements were carried 
out with a temperature-controlled Beckman XL-I analytical ultracentrifuge equipped 
with an An-60 Ti rotor and a photoelectric scanner (Beckman Instruments, Palo Alto, 
CA). For equilibrium experiments, varying concentration (20 µM, 25 µM and 35 µM) of 
P2-RANTES were carried out in the buffer containing 50 mM Tris-Bis, pH 5.0, with 200 
mM NaCl. Samples were loaded onto the 12 mm aluminum 6 channel centerpiece and 
set the speed for 35,000 rpm, 45,000 rpm and 55,000 rpm at 20°C for 16 hours for each 
speed in a step scan model. For velocity experiments, 40 µM of P2-RANTES was 
carried out in the buffer containing 50 mM Tris-Bis, pH 5.0, with 1000 mM NaCl. 
Protein sample was loaded in a double sector 12 mm aluminum centerpiece and at a 
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rotor speed of 60,000 rpm at 20°C for 24 hours in a continues scan model. For both 
equilibrium and velocity experiments, the reference compartments were loaded with the 
matching buffer without proteins and samples were monitored the absorbance at 280 nm 
with setup rotor speed.  Analysis of the raw data was carried out using UltraScan version 
8.0 (http: //ultrascan.uthsca.edu).  The partial specific volume of P2-RANTES was 
estimated using the amino acid composition methods implemented in UltraScan. The 
hydrodynamic corrections for buffer conditions were calculated by UltraScan. For the 
equilibrium experiments, data were analyzed using the Global Nonlinear Least-Squares 
fitting methods implemented in UltraScan. The equilibrium data are also applied to the 
Origin program (Beckman), and the fitting results are very consistent with UltraScan. 
For velocity experiments, data were analyzed using the enhanced van Hode-Weschet 
method, which reports sedimentation coefficient distributions transformed into 
molecular weight distributions by applying the Svedberg equation and assuming a 
particle shape that corresponds to an expected frictional ratio, f1/f0 (184,185).  
Nuclear magnetic resonance 
     15N labeled wild type RANTES and P2-RANTES were produced in 15-NH4Cl 
isotopically labeled minimal medium following the standard procedure. The purified 
lyophilized powders were dissolved in 10% D2O with 20 mM sodium phosphate, pH 3.0. 
The samples were placed in Shigemi tubes (Allison Park, PA) and the spectra referenced 
relative to DSS (123). NMR spectra were acquired at 25 °C on a Varian Unity Plus 500 
MHz spectrometer equipped with an xyz gradient penta probe. 15N-1H HSQC 
(heteronuclear single quantum coherence) spectra were collected with 512* points in the 
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proton dimension and 128* points in the nitrogen dimension. A spectral width of 6000 
was used in the 1H dimension and 1500.68 Hz for 15N. The data were processed using 
the program nmrPipe (124) and analyzed using the program PIPP (125).  
Cell-cell fusion assay 
     Envelope-mediated cell-cell fusion assays were carried out as described in reference 
(179,180) with HeLa-P5L and HeLa-ADA cell lines with minor modifications. Briefly, 
HeLa-P5L 104 cells were seeded in 96-well culture plate in 50µl RPMI-1640 medium 
per well for 2-3 hours. For 3T3 competition assay, HeLa-P5L cells104 in 25µl were 
mixed with 1×105 3T3 cells in 25µl for each well. The sample of P2-RANTES or T-20 
were added into the cell medium with serial dilutions from 4 µM to 0.4 pM (protein 
concentration was quantified by measuring the absorbance at 280nm using the extinction 
coefficient method published by Pace (186).)  After preincubation in 37ºC for 30 min, 50 
µl HeLa-ADA 104 cells per well in RPMI-1640 medium were added into 96-well culture 
plate. After further 24 hours of incubation at 37ºC for complete fusion, cells in the 96-
well culture plate were washed once by 1× PBS, lysed by adding 0.5% NP-40 
(USBiological) in PBS for 15 min at room temperature and assayed for β-galactosidase 
activity by the addition of 8 mM substrate CRPG in PBS with 20 mM KCl and 10mM β-
mercaptoethanol (Sigma) for 2 hours in the dark at room temperature. The A570 was 
read on Benchmark microplate reader (BioRad). The percentage of the cell-cell fusion 
was expressed as 100 × (mean absorbance of treated well - mean absorbance of HeLa-
P5L only well) / (mean absorbance of untreated well - absorbance of HeLa-P5L only 
well). Experiments were performed in triplicate, and dose dependent inhibition curves 
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were fitted with four-parameter logistic equation (187) using KaleidaGraph (version 3.6, 
Synergy Software). 
FACS analysis 
     HeLa-TZM cells (105) were incubated for 30min at 37°C in culture medium 
containing various concentrations of (0-100 nM) of drugs in 10× 75mm culture tubes 
(Fisher Scientific). After washing 4  times with 10 mL cold PBS, cells were incubated in 
300 µl of  500 µg/ml mouse anti-human CCR5 monoclonal antibody in PBS-0.5% BSA 
(Sigma),  and kept on ice for 45 min. The cells were then washed 3 times with  cold 
PBS-0.5% BSA and incubated in 300 µl of 50 µg/ml FITC labeled  polyclonal goat anti-
mouse antibody in PBS-0.5% BSA, and kept on ice  for 30 min. 1 aliquot of untreated 
cells  were incubated with PBS-BSA for 30 minutes followed by 3 washes 
and  incubation with the FITC-labeled goat anti-mouse IgG as control. Then the cells 
were washed 3 times with cold PBS-0.5% BSA and kept in  PBS-0.5% BSA, and 
analyzed with a FACSCalibur (BD Biosciences, San  Jose, CA) flow cytometer using 
CellQuest (BD Biosciences) acquisition  software. Cell viability was determined by 
staining with propidium iodide (PI) at 1µg/ml final concentration 1 minute prior to 
analysis.  FITC fluorescence was collected through a 515/30 band pass filter, and PI 
fluorescence through a 650LP filter. List mode data were acquired on a minimum of 
10,000 viable cells defined by a light scatter and  lack of PI staining. Data were analyzed 
using FlowJo (Tree Star, Inc., Ashland, OR). First, a region to define cells was set using 
a forward and side light scatter plot, then viable (PI-negative) cells  were determined by 
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a plot of forward light scatter and PI  fluorescence. Results are presented as histograms 
of FITC fluorescence. 
Heparin sepharose chromatography of GAG binding studies. 
     GAG binding capacity of chemokine mutants were studied using heparin Sepharose 
chromatography as mentioned in previous publications (188).  Briefly, equal amounts of 
wild type RANTEE and P2-RANTES (approximately 10 µg of lyophilized protein) was 
taken up in 0.5 mL of 50 mM Tris (pH7.4) and injected onto a 1 mL Hi-Trap heparin 
column (Pharmacia) using the AKTA HPLC system (GE Healthcare). The column was 
equilibrated with 5 mL of the same buffer followed by a gradient of 0 to 1200 mM NaCl 
in 50 mM Tris (pH7.4) at a rate of 0.5 mL/min for 60 min. The elution profile was 
monitored by UV absorbance at 280nm. The salt concentration corresponding to the 
center of each eluted peak is a relative determinant of the GAG binding ability of that 
mutant. Experiments were performed in duplicate and the results were reported as 
average plus the standard deviation. 
 
Results 
Protein production and characterization 
     The RANTES mutant (P2-RANTES) was overexpressed largely as inclusion bodies 
in the E. coli strain Bl21 (DE3). By utilizing a refolding protocol followed by proteolysis 
of the fusion tag, the tag free P2-RANTES was found to be folded as judged by NMR 
(Figure 4-2). The 15N-1H HSQC (Heteronuclear Single Quantum Coherence)  
 
  
93
 
Figure  4-2:  In the NMR-HSQC experiments each peak corresponds to each covalently 
bonded 15N-1H pair in the protein. The chemical shift position of a peak is dependent on the 
local molecular environment. If the protein is folded, all peaks will be nicely spread in the 
1H dimension, because each individual peak has a unique conformation. If the protein is 
not folded, all peaks will be in the middle of the spectrum and not spread because all 15N-
1H bonds are similar to each other.  The peaks from P2-RANTES are nicely spread 
indicating that the protein P2-RANTES is nicely folded. The overlay of P2-RANTES(red) 
with wild type RANTES (black) reveals that these two proteins have very similar 
“fingerprint” and highly are similar in structure.  
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experiment provides a spectrum showing a single peak corresponding to each covalently 
bonded 15N-1H pair in the protein. The chemical shift position of a peak is dependent 
on the local molecular environment and as a result the HSQC spectrum for each protein 
is unique,  providing a “fingerprint” of the protein. The overlay of spectrum of P2-
RANTES (red) with wild type RANTES (black) indicates that P2-RANTES has similar 
“fingerprint” as RANTES protein. Moreover, P2-RANTES has about 60 peaks while the 
wild type RANTES has about 80 peaks. This may indicate this mutant has a different 
oligomerization state. Further experiments using ultracentrifugation were applied to this 
matter in a later section of this chapter. The Mass spectrum indicated that the protein is 
nearly 97% pure and the molecular weight is 7894 ±8 Dalton (Figure 4-1). This matches 
closely the calculated molecular weigh 0f 7906 Dalton. This indicates that P2- RANTES 
produced from the E. coli overexpression has the expected amino acids composition.  
Anti-HIV fusion function 
     In order to test the biological function of P2-RANTES produced from the E. coli 
overexpression, we carried out an HIV R5 tropic env mediated cell-cell fusion assay. 
The 50% inhibition of the cell-cell fusion for P2-RANTES is 0.71± 0.09 nM (Fig 4-3). 
This is the same as the published results of P2-RANTES produced using complete 
chemical synthesis (100). Moreover, we also found that this potent anti-HIV chemokine 
mutant has advantages over the widely used fusion inhibitor: T-20.  
    There are several studies revealing that T-20 in addition to bind to gp41 can bind to an 
undefined target such as cell membranes or lipids (77,104,108,109). This could  
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             Figure 4-3:   Dose dependent inhibition curve in the R5-tropic cell-cell fusion assay 
with or without the competitive 3T3 cells. The inhibition of HIV-1 fusion is 
presented using the plot of the percentage of fusion versus the concentration (nM) 
of T-20 (with 3T3, black filled circles; without 3T3 cells, black open circles), P2-
RANTES (with 3T3 cells, red filled circles; without 3T3 cells, red open circles) in 
the HeLa-ADA and HeLa-P5L R5 tropic cell-cell fusion assay. Error bars indicate 
the triplicate standard deviation (± SD). Curves were fitted with four-parameter 
logistic equation using KaleidaGraph.  The IC50 for T-20 with and without 3T3 
cells are 193 ± 62 nM and 5.1 ± 0.8nM respectively. The IC50 for P2-RANTES with 
and without 3T3 cells are 0.027 ± 0.003 nM and 0.71 ± 0.09 nM respectively.  
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explain the high dose requirement when T-20 is administered in the clinic. In our cell-
cell fusion experiments, we tried to change the standard assay to use in vitro conditions 
to mimic the actual cell environment in vivo:  Mice 3T3 cell which do not contain human 
CD4, CCR5 or HIV env on the surface were used as a competitor. Without the 3T3 
competitive cells, (i.e. in a standard HIV cell-cell fusion assay) T-20 was shown to have 
50% inhibition at 5.1 ± 0.8 nM. With the 3T3 competitive cell present (105 3T3 cell / 
well, 1e4 HeLa-ADA / well,104 HeLa- P5L / well), T-20 was shown to have 50% 
inhibition 193 ± 62 nM (Figure 4-3). This significant decrease (~40 fold) of potency in 
the inhibition of cell-cell fusion of T-20 is only due to the presence of 3T3 cells because 
the control wells (HeLa-P5L cell only as negative, HeLa-P5L adding HeLa-ADA 
without treatment as positive) with 3T3 cells and without 3T3 cells did not show any 
significant difference (data not shown). In the same experiment, P2-RANTES was 
shown to have 50% inhibition 0.027± 0.003 nM when 3T3 cells are present and 
0.71±0.09 nM when 3T3 cells are absent (Figure 4-3). The dramatic increased (~25 fold) 
in potency of inhibition of cell-cell fusion is only due to the presence of the competitive 
3T3 cells. This effect can be explained by the strong selectivity of P2-RANTES to CCR5. 
When competitive 3T3 cells are present, the HeLa-ADA cells (representing the HIV 
surface) may have less chance to recognize the target cells. In this situation, the overall 
fusion is less efficient, making apparent inhibition by P2-RANTES more efficient. The 
fusion is more difficult to inhibit by T-20 when competitive 3T3 cells are present 
because T-20 has nonspecific interactions to unrelated cell membrane or lipids 
(77,104,108,109). 
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Figure 4- 4:   CCR5 internalization induced by wild type RANTES and P2-RANTES in the 
steady–state CCR5 down modulation FACS experiment.  Data are plotted as 
histograms of fluorescence intensity (cell surface CCR5), with the cell 
number normalized for each sample.  FITC fluorescence intensity from different 
concentration drug treated HeLa-TZM and stained with same CCR5 antibody and second 
antibody are presented with different color: black (0 nM); red (1 nM); blue (10 nM) and 
green (100nM).  The cells stained without CCR5 antibodies are showed as gray curve.   
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This result may also be explained that P2-RANTES can strongly reduce the 
expression of CCR5 on the target cell, which lead to a longer period windows for the 
prehairpin state of gp41. This result may need further investigation in future. But the 
overall function of P2-RANTES in the same experiments is much greater than T-20. 
Without competitive cells, P2-RANTES has ~10 fold improvement compared to T-20. 
With competitive cells, P2-RANTES has ~6000 fold improvement compared to T-20. 
CCR5 down modulation 
       As mentioned by Hartley (100) there are two mechanisms underlying improved anti-
HIV activity of P2-RANTES: increased binding affinity for CCR5 and enhanced 
capacity of internalization of CCR5. We repeated similar CCR5 internalization 
experiments. Compared to wild type RANTES, P2-RANTES produced in our hands also 
showed stronger capacity to reduce the CCR5 expression level in steady-state CCR5 
down modulation experiments than the wild type RANTES. As show in Figure 4-4, in 
the FACS experiments, P2-RANTES was shown to strongly internalize CCR5 
expression on the HeLa-TZM cell in a concentration dependent manner while the wild 
type RANTES control did not show any significant changes using the same set up. This 
is in agreement with previously published work with different CCR5 expressing cell 
lines using a synthesized P2-RANTES polypeptide (100). 
GAG binding studies 
       Most chemokines are highly positively charged. This property facilitates the binding 
to GAGs on the surface of cells, which immobilizes and presents the chemokine  
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Figure 4-5:  Heparin sepharose chromatography of wild type RANTES and P2-RANTES. 
Equal amounts of wild type RANTES and P2-RANTES were loaded onto a heparin 
sepharose column and eluted using a NaCl gradient. The dashed lines indicating the elution 
gradient. The experiments from duplicate indicate that the gradient for wild type RANTES 
is 698 ± 5mM and P2-RANTES is 550 ± 3 mM.  
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gradients for chemotaxis. Previous studies of AOP-RANTES indicated that the AOP 
group may alter the GAG binding capacity (178). We wanted to verify whether the N- 
terminal amino acid mutagenesis modification of RANTES, P2-RANTES has any effect 
on the GAG binding capacity. The result of our heparin column binding studies 
suggested that P2-RANTES indeed has less capacity to bind GAG compared to the wild 
type protein. As shown in Figure 4-5, when the same amount of protein was loaded onto 
the heparin column with low salt, the wild type RANTES was found to require 698 ± 5 
mM NaCl to completely elute, while P2-RANTES eluted around 550 ± 3mM NaCl. This 
result indicates that the N-terminal modification of P2-RANTES reduced the GAG 
binding capacity compared to wild type RANTES. 
Analytical ultracentrifugation sedimentation 
       RANTES can dimerize in solution as many other chemokines (15,16). The 
dimerization of RANTES or other chemokines plays an important role in the regulation 
of  GAG binding (9,29,189). Since P2-RANTES shows a different profile of GAG 
binding compared to the wild type RANTES, it may indicate that P2-RANTES has a 
different oligomerization state (Figure 4-5). We carried out analytical ultracentrifugation 
sedimentation equilibrium and velocity experiments to determine the quaternary 
structure of P2-RANTES. Our results with multiple concentrations and multiple speeds 
suggest that P2-RANTES is predominantly in a monomeric conformation in solution. As 
show in Figure 4-6, the sedimentation equilibrium experiments revealed that P2-
RANTES fits the single component model. The data can not fit to either the monomer-
dimer equilibrium or the monomer-tetramer equilibrium model. The fitted molecular  
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Figure 4-6: Oligomerization state of P2-RANTES in solution. The selected AUC 
sedimentation equilibrium experiment (24 µM of P2-RANTES in 50mM Tris-Bis, 200 mM 
NaCl, pH 5.0, speed rate at 55,000rpm) is showing with the raw data by the plot of 
absorbance at 280nm versus the radius,  and curve fitting with the single component model. 
The fitted molecular weight (MW) is around 7.7 kDa in this set up using the Origin 3.78 
(Beckman) program while the calculated MW from amino acid composition is 7.9 kDa.   
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Figure  4-7:  AUC sedimentation velocity experiment showing boundary movements in the 
plot of absorbance at 280nm versus the radius in cm. 
 
 
 
 
 
Figure  4-8:  Species of population versus molecular weight by converting the raw 
sedimentation velocity data. Molecular weight distribution of P2-RANTES at 50mM Tris-
Bis, pH5.0, 1000 mM NaCl indicates that 90% of the population is a monomer (around 8 
kDa) and 10% of the population is a dimer (around 16 kDa). 
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weight is around 7.7 kDalton in solution conditions: 50mM Tris-Bis, pH5.0, 200mM 
NaCl.  Other studies suggested that the chemokine oligomerization is salt dependent  
with more salt generally favoring the dimer (29,115). We therefore carried out further 
sedimentation velocity experiments with higher salt concentrations: 50mM Tris-Bis, pH 
5.0, 1000mM NaCl. We transformed the raw sedimentation experiments (Figure 4-7) 
into the species population plot using the enhance Hode-Weschet method implemented 
in the UltraScan (184,185) .  As shown in Figure 4-8, 90% of the population of P2-
RANTES is a monomer and 10% of the population is a dimer. This indicates that again 
P2-RANTES is predominantly a monomer but it has the tendency to dimerize under 
certain conditions (for instance high concentration of salt). 
Structure determination and description 
     The crystal structure of P2-RANTES was determined in collaboration with Dr. 
Pingwei Li. The crystal structure of P2-RANTES is well defined in 1.7Å resolution with 
the R free factor 24.8% (Table 4-1). The overall structure of P2-RANTES is a 
homotetramer containing four subunits, labeled as chain A, B, C and D (Figure 4-9). 
Chain A and chain B have a completely defined structure from residues Phe0 to Ser 68. 
The N-terminal mutated region in chain A and B is clearly defined due to the restraints 
of the oligomerization (Figure 4-10). The N-terminal mutated region in chain C (Phe0-
Ser4) and chain D (Phe0-Ser5) is disordered, but the rest of the core structure, from 
residue (chain C: Ser5 to Ser68; chain D: Ser6-Ser68), are well defined. All monomers 
of P2-RANTES from chain A to D share the same topology as other CC and CXC 
chemokines monomers, with three anti-parallel β sheets and an α-helix connected to the  
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Figure 4-9:  Structure of P2-RANTES.   Overview of the tetramer structure of P2-
RANTES. The four subunits in this ribbon drawing are labeled with A (blue), B (cyan), C 
(green) and D (yellow).  
 
 
 
Figure 4-10: Close-up view of N-terminal residues of a P2-RANTES monomer A. Based on 
the electron density map,  the N-terminal residues, from Phe0 to Ser8 ( stick model) are 
clearly defined due to the restraints of oligomerization.  
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third β-sheet with a flexible loop. Two left-handed disulfide bridges (Cys10-Cys34, 
Cys11-Cys50) restrain the overall core of the chemokine fold. A short β-sheet (β0) is 
formed in monomers chain A and chain B from residues Ser8 to Cys10. This region is 
reported to cause the dimerization for wild type RANTES (15,16,178,190), but the wild 
type RANTES has the Pro9 in the middle of β sheet, while P2-RANTES has Ala9 in the 
middle instead. This makes the β0-β0 dimer in P2-RANTES slightly weaker than wild 
type RANTES. All monomers contain a long loop (N-loop, sometimes referred to as the 
20’s loop) between Cys11 and Pro20. This loop region is  previously reported for the 
determinant of binding to CCR5 (136). After a short 310 helix (Arg21–His23, α0), there 
are three main anti-parallel β-strands formed by Ile24–Tyr29 (β1), Val39–Thr43 (β2) 
and Gln48–Ala51 (β3). The structure of all monomers end with a C-terminal α-helix (α1) 
formed by residues from Lys56 to Glu66 with extended residues Met67 and Ser68 as a 
tail. The loop between β1 and β2 contains a type III reverse turn (Ser31–Cys34, 
sometimes referred to as the 30’s loop); the loop between β2 and β3 contains a type I 
reverse turn (Thr43–Asn46, sometimes referred to as the 40’s loop); and the loop 
between β3 and α1 is a type I reverse turn (Asn52–Lys55, sometimes referred to as the 
50’s loop). Secondary structure elements were defined using the program CNS (183). 
     There are several contacts between monomer A and B that are involved in forming 
the wild type dimer. For example, the antiparallel β0-β0 interactions are formed by 
residues Ser8-Ala9-Cys10, hydrogen bonds are formed  between Ser7 (N) and Gln48’ 
(O), Ser7 (OG) and Gln48’ (OE1), Ser8 (N) and Cys10’ (O), Cys10 (N) and Ser8’ (O),  
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Figure 4-11: Close-up view of the contact interface between Phe0 of monomer A and the 
hydrophobic cleft of monomer C.  Based on electron density map, Phe0 (blue, stick model) 
from monomer A interacts to Phe28, Thr30, Ala9, Val40, Cys11, Cys50 (green stick model) 
of monomer C (green ribbon) by hydrophobic interactions.  
 
 
 
 
Figure 4-12: Close-up view of the contact interface between monomer B (cyan) and 
monomer C(green). The hydrophobic interactions are also found between monomer B and 
C: Try14 from monomer B to Ala16 from monomer C, Ala16 from monomer B to Tyr14 
from monomer C and Ala 13 from monomer B to Ala 16 from monomer C. Same as Figure 
4-11, Phe0 from monomer A (blue) interacts to Phe28, Thr30, Ala9, Val40, Cys11, and 
Cys50 of monomer C (green) by hydrophobic interactions. The residue Pro2 of monomer A 
also contacts to Ile15, Val49 and Ala13 of monomer C by hydrophobic interactions.  
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Cys50 (N) and Ser 5’ (O). This is slightly different from the AOP-RANTES(190) and 
Met-RANTES in which the hydrogen bonds are formed between Ser5 (O) and 
Cys50’(N), Asp6(N) and Gln48’(O) and Thr7(OG1) and Gln48’(OE1) (178). Phe12 has 
een shown to be important for binding to CCR5 and dimerization (191,192). In the P2-
RANTES dimer, between chain A and chain B, Phe12 is still intact and involved in 
corresponding interactions to create the dimer interface.  Comparison of the N-termini 
from both monomers shows the N-termini of monomer A to be better resolved and more 
highly ordered than monomer B, with clearer density and lower temperature factors.   
     Residue Phe0 from chain A (or chain B) contacts hydrophobic clefts on chain C (or 
chain D). As shown in Figure 4-11, based on theelectronic density map, Phe0 from 
monomer A interacts with Phe28, Thr30, Ala9, Val40, Cys11, Cys50 of monomer C by 
hydrophobic interactions. Residue Pro2 of chain A (or B) is also found to contact  Ile15, 
Val49 and Ala13 of chain C (or D) by hydrophobic interactions. The hydrophobic 
contacts between monomer B and C (or between A and D) are also found through Try14 
(chain B) to Ala16 (chain C), Ala16 (chain B) to Tyr14 (chain C) and Ala 13 (chain B) 
to Ala 16 (chain C) (Figure 4-12). However, the buried surface area of this dimer 
interface is much smaller compared to the dimer interface between monomer A and B 
(Table 4-2). 
Comparison of P2-RANTES structure with other crystal structures of RANTES 
     There is very little difference in the secondary structure between the crystal structure 
of P2-RANTES described here and the crystal structures of RANTES: Met-RANTES 
(193) and AOP-RANTES (190). The root mean square deviation (rmsd) values for  
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Table 4-2: The buried surface area of the dimer interface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RANTES variants Monomer 1
(Å2)
Monomer 2
(Å2)
 
Dimer  
(Å2) 
Buried 
surface 
area  (Å2)
 
A-B 5242 5286
 
9064 1464
A-C 5242 4692 9318 616
A-D 5242 4609 9082 769
B-C 5286 4692 9131 847
 
 
 
P2-
RANTES 
B-D 5286 4609 9257 638
RANTES wt (1rto) 5314 5316 9186 1444
AOP-RANTES (1b3a) 5125 4917 8081 1961
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Figure 4-13:  Overlay of monomer structure of P2-RANTES (red) to Met-RANTES (gray) 
and AOP-RANTES (purple). The conserved four Cys residues set as a control to 
superimpose the monomer structure of these three using the “super match” function 
implemented in UCSF Chimera (194). Most of the core structures are well overlapped. The 
most different part are the N-terminal regions. In P2-RANTES, Pro9 is mutated into Ala, 
Thr7 is mutated into Ser, Thr8 is mutated into Ser, Asp6 is mutated into Gln and Tyr3 is 
mutated into Leu3. All these mutations make the N-terminal dimer contacts weaker than 
wild type RANTES. The extended residue Phe0 is pointing in a completely different 
direction compared to the AOP group.   
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superpositioning the backbone atoms of P2-RANTES residues 6–68 onto the equivalent 
atoms of the 1eqt (Met-RANTES) and 1b3a (AOP-RANTES) structures are 0.461 Å and 
0.461 Å, respectively.  But, there is a lot of difference in the N-terminal regions as seen 
in the overlay of these three crystal structure (Figure 4-12). In contrast to Met-RANTES 
structure, in which the conformation of the first 3 residues was not determined, the 
extended Phe0, Ser1, Pro2 and Leu3 are seen quite clearly in the P2-RANTES crystal 
structure between monomer A and monomer B (Figure 4-12). Moreover, in AOP-
RANTES and Met-RANTES, there are contacts between the peptide Pro2–Tyr3 of one 
monomer and the symmetry-related ring of Tyr29, which cause the N-termini to push 
closer to the protein. In P2-RANTES, the Tyr3 is mutated to Leu, this seems to push 
monomer B away from monomer A. This seems to make a less packed dimer interface 
that can explain why the protein is mainly a monomer in solution. 
               The largest differences are found at the dimer interface. The sparse contacts 
between the monomers of P2-RANTES seem to allow the dimer to flex, as seen in a 
comparison of the P2 RANTES dimer with Met-RANTES and AOP-RANTES. 
Although the two monomers are linked through a short β0-β0 interaction by residues 
Ser8–Cys10, the relative orientations of the monomers to each other are quite different. 
The dimeric structure of P2-RANTES is less compact than the AOP-RANTES structure, 
as reflected in the total buried surfaces (Table 4-2) (Figure 4-13). AOP-RANTES (1b3a) 
buries 24% of the total monomeric solvent accessible surface on dimerization (monomer 
A = 5125 Å2, monomer B = 4917 Å2, dimer = 8081 Å2), whereas P2-RANTES bury 
only 16% (monomer A = 5451 Å2, monomer B = 5429 Å2, dimer = 9142 Å2). The 
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difference in the buried surface area between P2-RANTES and AOP-RANTES is due 
mainly to the tight fit between the Pro2 and AOP groups wrapped around the surface of 
the neighboring monomer while Pro2 and Phe0 in P2-RANTES are pointing in different 
directions (Figure 4-13, 4-14).       
    Monomers A and B of P2-RANTES shows the N- termini to be clearly defined and 
the extended Phe0 bound to the hydrophobic clefts of monomer C and D. This is very 
different to the disordered amino terminus of native RANTES, and different to AOP-
RANTES which the AOP group binds to the surface of the other monomer (190). As 
seen in AOP-RANTES, movement of the N- terminus from solution to the surface might 
therefore disallow specific interactions with CCR5. Or, these interactions seen in the 
crystal structure may reflect the interaction on how the N-termini of RANTES inserts 
into the transmember region to trigger transduction signaling. Very interestingly, in P2-
RANTES the Phe0 is not moved back to the surface of the other monomer as seen in the 
AOP group, but it is pointing toward the hydrophobic cleft of monomer C (or D) instead.  
Alternatively, the presence of the extended Phe0, mutation Tyr 3 to Leu,  mutation  of 
Pro9 to Ala might disturb the monomer/dimer equilibrium, which might or     might not 
play a role in receptor binding and activation. Without a complete understanding of 
chemokine receptor activation, it is difficult to state the reasons for the antagonist 
properties of P2-RANTES. Further studies of other RANTES derivatives would be 
helpful in evaluating different hypotheses.  
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Figure 4-14: Overlay of the dimer structure of P2-RANTES to Met-RANTES and AOP-
RANTES.  Monomer A from P2-RANTES was set as reference, all dimer structures were 
overlaid by “super match” function implemented in UCSF Chimera (194). It shows that 
monomer to monomer orientation in the dimer of P2-RANTES (red) is very different to 
AOP-RANTES (purple) or Met-RANTES (gray). Especially, due to the N-terminal regions 
mutations, the lacking of dimer contact in P2-RANTES makes the C-terminal α-Helix 
orientate away from the referenced monomer. Beside, Phe0 (red stick model) is pointing 
very different direction comparing to AOP group (purple stick model). Other residues 
including Ser1, Pro2 and Tyr3 (in P2-RANTES is Leu3) are all showing different 
orientation. All figures were made using UCSF Chimera (194). 
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Discussion 
     RANTES possesses the unique capacity to bind and activate a range of receptors 
including CCR1, CCR3, CCR4 and CCR5. In order to make it a more potent anti-HIV  
entry inhibitor, Hartley et al. improved CCR5 binding affinity and CCR5 selectivity 
using a phage display, resulting in the mutant, P2-RANTES (100). The structure studies 
of this mutant protein from our work revealed that in contrast to wild type RANTES 
which is a tight dimer both in solution and in crystallization conditions, P2-RANTES is a 
monomer in solution while it is unique tetramer in crystallization conditions.    
     The different quaternary structures between the solution (from AUC) and crystal 
forms of P2-RANTES correspond with obvious differences between monomer C (or D) 
and monomer A (or B). Residues 1-4 in monomers C and D structure are highly 
disordered as also seen in the crystal structure of Met-RANTES (178) or the NMR 
structure of wild type RANTES (15,16).  However, these residues protrude into the 
surrounding solvent as seen in monomers C and D, are closely packed at the dimer 
interface on monomer A and monomer B (as well as the dimer between monomer A and 
C) and contribute to the dimerization. The factors that promote stabilization of the N-
terminus and formation of complementary monomer-monomer interactions are not 
known.  
     P2-RANTES is a pure monomer in solution judged using analytical 
ultracentrifugation (Figure 4-6), but the crystal structure shown in this study is a very 
unique tetramer. Because of the tendency to dimerize in certain conditions (Figure 4-8), 
P2-RANTES might energetically favor a monomer in solution. But, with high 
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concentration and less solvent environment, for instance, in the x-ray crystallization 
conditions, P2-RANTES might favor the oligomerization state as we described here. To 
our knowledge, this is not an isolated case. Several chemokines are found to be a 
monomers in solution, but the crystal structures are oligomers (1,25,195). In binding 
assays and activation assays reported by Hartley, the residue Phe0 seems to be very 
critical for its function (100). Here, the reported structure of P2-RANTES also indicates 
that Phe0 is very important in forming the unique tetramer structure. But it is not clear 
whether this structural importance reflects a functional importance. Further studies of a 
complex between P2-RANTES with CCR5 would be helpful in evaluating on how P2-
RANTES directly interact with CCR5.  
     Moreover, it is well-known that at physiological conditions RANTES can form 
higher-order oligomers at high concentration (15) or in the presence of GAGs (160). It 
has been shown in several studies that GAG binding can alter the oligomermization of 
chemokines (9,29). Yet the exact role of the extension of Phe0 in this effect is not known. 
It possibly is due to a change in transfer to the cell surface as mediated by GAG, 
although the binding to GAG has been shown to be mediated primarily by positively 
charged residues on a surface far from the N-terminus. The attachment of aromatic Phe0 
to the amino terminus alters the chemical nature and surface features of the RANTES 
molecule. Several other mutations, such as Tyr3Leu, Asp6Gln, Thr7Ser, Thr8Ser and 
Pro9Ala also strongly reduce the dimerization as seen in the structure. Also,  as we 
showed in the Heparin column results, P2-RANTES lost one third of its capacity to bind 
to GAG (Figure 4-5). This could give rise to the possibility that P2-RANTES strong 
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anti-HIV-1 fusion activity is due to its binding less to GAG on the cell surface. This may 
also need further investigation to clarify. 
     Although it is not clear exactly how the extended residue Phe0 in P2-RANTES 
interacts with CCR5, comparison of the N-termini of the structure that we reported here 
to other available RANTES crystal structure, shows that Phe0 is largely different with 
Met0 in Met-RANTES or AOP group in AOP-RANTES:  Met0 is undefined in the 
crystal structure; the AOP group folds back onto the surface of the other monomer. Phe0, 
however, is pointing away from the dimer of monomer A and monomer B and binds to 
the hydrophobic cleft of monomer C. Since Phe0 is critical for the function for P2-
RANTES, this might indicate that Phe0 interacts with CCR5 in a different manner 
compared to the AOP group interacting with CCR5. In the crystal structure we showed 
here, Ser1 is pointing in the same direction as the AOP group, it may be very interesting 
to mutate Ser1 to Phe to see whether the property of blocking HIV entry can be affected. 
Interestingly, a novel natural mutant Ser1Phe of wild type RANTES was reported in a 
recent paper from 95 Cameroon samples (196). This mutant was found to only activate 
CCR5 not CCR1 or CCR3 (196). This might suggest that, as we showed in the structure 
here, Ser1 is pointing in a similar direction as the AOP group.  
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CHAPTER V 
STRONG SYNERGY BETWEEN CC CHEMOKINES AND FUSION 
INHIBITORS LEADS TO POTENT EFFECTIVE ANTI-HIV-1 AGENTS IN 
BLOCKING CELL-CELL FUSION AND VIRUS INFECTION 
 
Introduction 
     In addition to the more established anti-HIV-1 strategies such as inhibition of 
protease or reverse transcriptase, viral entry inhibition has great potential in the fight 
against AIDS.  Entry inhibition entails stopping HIV-1 before it breaches the cell, either 
as a strategy to prevent infection altogether or to curtail infection of new cells in an HIV-
positive individual.  Several strategies have proven effective at HIV-1 entry inhibition 
either in vitro or in vivo: binding to viral surface proteins gp120 and gp41, binding to 
human cell surface receptor CD4, and binding to human cell surface co-receptors CCR5 
and CXCR4 (1,77,161,197).  In particular, the synthesized peptide T-20 is believed to 
act by binding to gp41 (198,199) and is currently in clinical use. But several recent 
studies revealed that T-20 does not block the six-helix bundle pre-hairpin formation 
(104,197). Another peptide, C37, derived from C-terminus of gp41 (covering the widely 
reported C-peptide C34 (101,104,200)) is also reported to have strong anti-HIV entry 
activity due to tightly binding to the gp41 N-terminal helices; this peptide can be easily 
produced through E.coli. overexpression (200,201). 
     The potential for synergy between two entry inhibitors is an important for two 
reasons. First, the therapeutic dose of the drugs will be lowered, and second, the ability 
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of the virus to develop resistance to two agents at the same time is harder than to a single 
agent. Several studies have established that synergy can occasionally be observed when 
two fusion inhibitors are combined in a viral assay or in vitro fusion assay (202-208).  
For example, some synergy is observed in the combination of CCR5 antibodies with T-
20 (202,204), the combination of  small molecular antagonists of coreceptors with T-20 
(207,208), combination of small molecular antagonists of CCR5 with CCR5 antibodies 
(202,204,206) and  the combination small molecular antagonists of CCR5 with 
chemokines (204,207).  A potent synergy was observed between PRO 542 (a multivalent 
CD4-immunoglobulin fusion) and T-20, in which the IC50 of each component was 0.84 
nM and 1.3 nM, respectively, but in combination the IC50 was reduced to 0.039 nM and 
0.35 nM, respectively in cell-cell fusion assays (205).   
     In this study I report that potent synergy can also be observed when CCR5 ligands 
MIP-1β and RANTES are combined with gp41 binding peptides C37 and/or T-20.  In 
particular, a combination of the RANTES mutant P2-RANTES (100)  and C37 in a fixed 
10:1 ratio yields an IC50 of  1 pM and IC90 of  39 pM in an R5 tropic cell-cell fusion 
assay, which we believe to be the most potent combination of entry inhibitors yet 
reported.         
 
Experimental Procedures 
Reagents  
           All cell culture media and supplements and fetal bovine sera were purchased from 
Invitrogen (Carlsbad, CA). Fusion inhibitor (N-acetylated derivative), T-20 (catalog No: 
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9845) was obtained from the NIH AIDS Research and Reference Reagent Program 
through Roche. The gene of HIV (HXB2) (catalog number: 1069) env was obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAD, NIH: HXB2-env from Dr. Kathleen Page and Dr. Dan Littman (209).  Mouse 
monoclonal antibody to human CCR5 was obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAD, NIH:  mouse anti human 
CCR5 monoclonal antibody from R&D system (catalog number: FABSP1, clone: 
45502). FITC (fluorescein isothiocyanate) labeled F(ab')2 fragment of polyclonal goat 
anti-mouse IgG second antibody was purchased from Sigma (catalog number: F 2653). 
PHA-P (catalog number: L8754) and AZT (catalog number: A2169) were purchased 
from Aldrich-Sigma (St.Louis, MO). IL-2 (catalog number: 0801017) and the Retro-Tek 
p24 antigen ELISA kits (catalog number: 0801200) were purchased from Zeptometrix 
Corp. (Buffalo, NY).  
Protein production and purification 
     For wild type chemokine MIP-1β and RANTES,  protein expression and purification 
followed a standard chemokine refolding and purification method published previously 
(29,47,138,188).   
     For the C37 peptide, its corresponding gene (200) was amplified through standard 
thermocycling using the gene of HIV (HXB2) env as template, adding the sequence of a 
Factor Xa cutting site upstream. The PCR product was placed into pET15b (Novagen, 
Madison, WI) at the Nde I-BamH I sites, and the DNA sequence of this mutant was 
  
119
confirmed through DNA sequencing.  When it is expressed, the protein has a 6 histidine 
tag on the N-terminus that is subsequently cleaved.  
     The gene for the RANTES mutant, P2-RANTES, was amplified through standard 
thermocycling using the wild type RANTES as template (100), also adding the sequence 
for a Factor Xa cutting site upstream.  This was inserted into  pET32-Xa (Novagen) at 
the Nde I-BamH I sites, and the DNA sequence of this mutant was confirmed through 
DNA sequencing. Upon expression, the protein has a 6 histidine tag and a thioredoxin 
fusion protein thioredoxin on the N-terminus to facilitate the purification.  When the 
fusion tag is removed (see below) the N-terminus of the P2-RANTES is exactly as 
published (100). 
     For production of peptide C37 and protein P2-RANTES, a slight variation on the 
standard chemokine refolding procedure was used. Protein production was induced by 
addition of IPTG to 1 mM in 37ºC culture of BL21(DE3) (Novagen) bearing the 
constructed plasmids for 7 hours, and the cells were harvested by centrifugation at 6,000 
x g in an F10S-6X500y rotor (Piramoon Technologies Inc.) for 30 minutes. The cells 
were resuspended in 30 mL of 500 mM NaCl, 20 mM Tris (pH 8), and 10 mM 
benzamidine and French pressed twice at 16,000 psi. After centrifugation for 30 minutes 
at 17,000 x g in an SS34 rotor (Sorvall Instruments), the pellet was resuspended in 20 
mL of 5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl.  The solution was 
stirred overnight and then centrifuged for 30 minutes at 17,000 x g to remove remaining 
insoluble pellet. The soluble denatured proteins were loaded onto a 5 mL chelating 
column (Amersham Pharmacia Biotech) equilibrated with same buffer (5 M 
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guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl).  The denatured proteins were 
purified through the chelating column using a gradient from 10% to 100% of 500 mM 
imidazole in 5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl. The 
fractions containing purified denatured protein were pooled together and slowly shaken 
(50 rpm) for 2 hours at room temperature after adding β-mercaptoethanol to 10mM. The 
purified denatured proteins were dialyzed against 20 mM Tris-HCl, pH 8.0 buffer 
overnight at 4ºC.  After dialysis, precipitated matter was removed by centrifugation for 
30 minutes at 15,000 x g in an F14S-6X250y rotor (Piramoon Technologies Inc.) and the 
protein was purified on a C4 reversed phase chromatography column (Vydac, Hesperia, 
CA), and lyophilized by the Labconco freeze dry system (Labconco Corporation).  To 
remove the fusion tag, the protein powder was solubilized into ~1mL of 20 mM sodium 
phosphate (pH 2.5) and the volume was increased to ~ 40 mL in 20 mM Tris (pH 8), 
50mM NaCl, and 2 mM CaCl2.  Factor Xa (Novagen) was used for the proteolytic 
cleavage, which typically took 2 weeks at room temperature.  SDS-PAGE was used to 
monitor the cutting reaction.  Finally, the cut proteins were purified over a C4 reversed 
phase chromatography column and lyophilized into powder. 
Cell culture  
      The HeLa cell line stably expressing HIV-1 ADA (R5) env (referred to as HeLa-
ADA) was a kind gift from Dr. M. Alizon (Cochin Institute, Paris, France) (179). Cells 
were cultured in DMEM supplemented with 10 % FBS, and 100 units of penicillin and 
0.1 mg/ml of streptomycin and the ADA (R5) env was selectively expressed by adding 2 
µM methotrexate (Sigma) as previously published (100,179,180). A HeLa cell line 
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stably expressing human receptor CD4 and CCR5 (referred to as HeLa-P5L) was a kind 
gift from Dr. M. Alizon (Cochin Institute, Paris, France) (179). Cells were cultured in 
RPMI-1640 (Invitrogen) supplemented with 10 % FBS, and 100 units of penicillin and 
0.1 mg/ml streptomycin. The expression of CCR5 was selectively expressed by adding 
zeocin (Invitrogen) 0.5 mg/ml.  A HeLa-TZM cell line was obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-
bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. (181,210,211). The 
cells were cultured at DMEM supplemented with 10% FBS, 100 units of penicillin and 
0.1 mg/ml of streptomycin as mentioned in the instructions provided by the NIH-ARRR. 
Cell-cell fusion assay  
     Envelope-mediated cell fusion assays were carried out as described (100,175,179,180) 
with HeLa-P5L and HeLa-ADA cell lines (100,175,179,180), with minor modification. 
Briefly, 104 HeLa-P5L cells were seeded in a 96-well culture plate in 50 µl RPMI-1640 
medium per well for 2-3 hours. The individual chemokine or the combination of 
chemokines with C37 or T-20 were added into the cell medium with serial dilution from 
4 µM to 0.4 pM.  Protein concentration was quantified by measuring the absorbance of 
the concentrated stock solution at 280nm using the extinction coefficient method 
published by Pace (186), followed by serial dilution.  After preincubation in 37ºC for 
30min, 50 µl HeLa-ADA (104 cells per well) in RPMI-1640 medium were overlaid into 
96-well culture plate. After a further 24 hours of incubation at 37ºC for complete fusion, 
cells in the 96-well culture plate were washed once by 1× PBS, lysed by adding 0.5% 
NP-40 (USBiological) in PBS for 15 min at room temperature and assayed for β-
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galactosidase activity by the addition of 8 mM substrate CRPG (chlorphenol red-β-D-
galactopyranoside, Calbiochem) in PBS with 20mM KCl and 10mM β-mercaptoethanol 
(Sigma) for 2 hours in the dark at room temperature. The absorbance at 570 nm was read 
on a Benchmark microplate reader (BioRad). The percentage of the cell-cell fusion was 
expressed as 100 × (mean absorbance of treated well - mean absorbance of HeLa-P5L-
only well) / (mean absorbance of untreated well - absorbance of HeLa-P5L-only well). 
Experiments were performed in triplicate, and dose dependent inhibition curves were 
fitted with a four-parameter logistic equation (187) using KaleidaGraph (version 3.6, 
Synergy Software). 
HIV infection assay 
     Peripheral blood mononuclear cells (PBMC) were isolated from  leucopaks (Gulf 
Coast Regional Blood Center, Houston, TX) drawn from eligible blood donors.  Blood 
was layered over a Ficoll-Paque Plus (GE Healthcare Bio-Scoience Corp, Pittsburgh, PA) 
gradient, and centrifuged. Buffy coats were harvested and washed 3 times with PBS, and 
the cells were subsequently placed in RPMI-1640 medium  supplemented with 20% FBS 
- 3% IL-2 - 5 µg/mL PHA-P, and allowed to stimulate for 2-3 days (37°C - 5% CO2) at 
a density of 1 × 106 PBMC/mL. Following stimulation, culture medium consisted of 
RPMI-1640 supplemented with 20% FBS - and 5% IL-2 (complete medium). 
Chemokines or combination with C37 initially diluted 1,000 nM in 5 mM sodium 
phosphate buffer, pH 3.0. Further serial working dilutions (from 500 nM to 5 pM) were 
made in complete medium, and were pre-incubated with the cells for a minimum of 1-2 
hours. Cells were plated in 24-well cell culture plates at a density of 2 × 106 PBMC/mL. 
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Each well, except for the negative virus control, received 50 µL containing sufficient 
virus to achieve a concentration of 1,000  TCID50  units of HIV-1 stock (R5 tropic strain, 
Ba-L) per 1 × 106 PBMC/mL and incubated overnight. During the initial 1-2 hours of 
incubation, the cell-culture plate(s) were agitated every 15 min to redistribute the virus 
dilution. Following overnight incubation the wells were washed 3 times with PBS to 
remove the virus, and each well received the analogous medium to that that was 
originally used to pre-treat the cells before virus infection. Following washing, the wells 
contents were split into three aliquots and placed into a 48-well cell culture plate (0.5 × 
106 PBMC/0.5 mL per well). Samples were composed of three replicates each. All cell 
culture plates were incubated as indicated above. ELISA testing of culture supernatants 
was typically done after 6-7 days to determine HIV-1 p24 levels. ELISA determinations 
were performed using the Retro-Tek HIV-1 p24 antigen ELISA kit (Zeptometrix Corp.). 
In each experiment, the positive inhibition control was treatment with 5 µM AZT and 
the negative inhibition control was no treatment of any kind. The percentage of 
inhibition was expressed as 100 × [1- (mean A450 of negative wells - mean A450 with 
drug treatment wells) / (mean A450 of negative wells- mean A450 of positive wells)]. 
Experiments were performed in triplicate, and dose dependent inhibition curves were 
fitted with four-parameter logistic equation (187) using KaleidaGraph (version 3.6, 
Synergy Software). 
Evaluation of synergy  
     Analysis of synergy, additivity or antagonism between chemokines and C37/T-20 
was performed using fixed ratios of drug combinations in antiviral assays according to 
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the median effect principle of Chou and Talalay (212). Chemokines and C37/T-20 were 
tested individually and in a fixed molar ratio combination over a range of serial dilutions 
(4 µM-0.1 pM range). The values of the doses required for percentage inhibition (IC5-
IC95) by each of the two drugs (alone and in combination), the Combination Index (CI), 
and the Dose Reduction Index (DRI) are calculated based on the published protocol from 
Chou (212) using Microsoft Excel. Based on this analysis, CI value reflects the nature of 
the interaction between the drugs. CI < 1 indicates synergy; CI = 1 indicates additivity; 
and CI > 1 indicates antagonism. The DRI is a measure of how much the dose of each 
drug in a synergistic combination is reduced at a given effect level compared with the 
dose for each drug alone. 
FACS analysis 
     HeLa-TZM cells (105) were incubated for 30min at 37°C in culture medium 
containing various concentration of (0-100 nM) of drugs in 10× 75mm culture tubes 
(Fisher Scientific). After washing 4  times with 10 mL cold PBS, cells were incubated in 
300 µl of  500 µg/ml mouse anti-human CCR5 monoclonal antibody in PBS-0.5% BSA 
(Sigma),  and kept on ice for 45 min. The cells were then washed 3 times with cold PBS-
0.5% BSA and incubated in 300 µl of 50 µg/ml FITC labeled polyclonal goat anti-mouse 
antibody in PBS-0.5% BSA, and kept on ice for 30 min. 1 aliquot of untreated cells were 
incubated with PBS-BSA for 30 minutes followed by 3 washes and incubation with the 
FITC-labeled goat anti-mouse IgG as control. Then the cells were washed 3 times with 
cold PBS-0.5% BSA and kept in PBS-0.5% BSA, and analyzed with a FACSCalibur 
(BD Biosciences, San Jose, CA) flow cytometer using CellQuest (BD Biosciences)  
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             Figure 5-1: The dose dependent inhibition curve in the R5-tropic cell-cell fusion 
assay for combination of chemokines with C37. The free C37 (black open circle), 
free MIP-1β (red open triangle), free RANTES(blue open square), C37 
combination (1 to 1 ratio) with MIP-1β(red filled triangle), and C37 combination 
with  RANTES (blue filled square) are presented using the plot of the percentage of 
fusion in the HeLa-ADA and HeLa-P5L R5 tropic cell-cell fusion assay versus the 
concentration (nM).  
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acquisition software. Cell viability was determined by staining with propidium iodide 
(PI) at 1ug/ml final concentration 1 minute prior to analysis.  FITC fluorescence was 
collected through a 530/30 bandpass filter, and PI fluorescence through a 650LP filter. 
List mode data were acquired on a minimum of 10,000 viable cells defined by a light 
scatter and  lack of PI staining. Data were analyzed using FlowJo (Tree Star, Inc., 
Ashland, OR). First, a region to define cells was set using a forward and side light scatter 
plot, and then viable (PI-negative) cells were determined by a plot of forward light 
scatter and PI fluorescence. Results are presented as histograms of FITC fluorescence. 
 
Results 
Cell-cell fusion assays 
     The CC chemokine MIP-1β has been shown to inhibit infection by HIV-1, 
and this ability to block entry helped lead to the discovery of CCR5 as the HIV-1 
coreceptor (80,213).  In later years, however, it became clear that MIP-1β was not as 
effective as other CCR5 ligands in HIV-1 inhibition (94,100,214).  As shown in Figure5-
1 and Figure5-2, MIP-1β alone does not significantly inhibit fusion in a standard in vitro 
fusion assay, nor is it notably effective in viral assays (12, 26 and unpublished).  Upon 
combination of MIP-1β with gp41-binding peptide C37 (1:1 ratio), significant inhibition 
of fusion is observed, but a comparison with C37 alone indicates that fusion inhibition is 
largely, if not completely, mediated by C37 itself (Figure 5-1).  Similarly, the 
combination of MIP-1β and fusion inhibitor peptide T-20 (1:1 ratio) shows only weak 
improvement over the effect of T-20 alone (Figure 5-2).  In each case, although some 
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             Figure  5-2: The dose dependent inhibition curve in the R5-tropic cell-cell fusion 
assay for combination of chemokines with T-20. The free T-20 (black filled circle), 
free MIP-1β (red open triangle), free RANTES (blue open square), T-20 
combination (1 to 1 ratio) with MIP-1β (red filled triangle),  T-20 combination with 
RANTES (blue filled square),  and T-20 combination with C37 (green open 
diamond) are presented using the plot of the percentage of fusion in the HeLa-ADA 
and HeLa-P5L R5 tropic cell-cell fusion assay versus the concentration (nM). 
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Table 5-1: Combination index values for the T-20 (and /or C37) in combination (1 to 1 ratio) 
with MIP-1β, RANTES and P2-RANTES in the HIV-1 (ADA) env mediated cell–cell fusion. 
 
 
 
 
 
 
 
 
 
Drugs Inhibitor 
one 
IC50, nM 
Inhibitor two
IC50, nM 
Combination of First 
Inhibitor and Second 
Inhibitor, IC50, nM 
Combinati
on Index 
MIP-1β/T-20 1000±100 1.65±0.79 0.49±0.25 0.29 
MIP-1β/C37 1000±100 8.31±1.21 7.27±1.39 0.887 
RANTES/T-20 109±126 1.65±0.79 0.56±0.26 0.344 
RANTES/C37 109±126 8.31±1.21 2.32±0.24 0.306 
P2-RANTES /T-20 0.88±0.25 1.65±0.79 0.0077±0.00099 0.0135 
P2-RANTES /C37 0.88±0.25 8.31±1.21 0.0080±0.0014 0.0101 
T-20/C37 1.65±0.79 8.31±1.21 0.63±0.21 0.487 
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synergy may be observable, it is not quantifiable because the lack of effectiveness of 
MIP-1β in the fusion assay made such calculations incomplete. 
     The CC chemokine RANTES has been shown to be more effective in fusion assays 
(and viral assays) than MIP-1β (94,100,214).  Therefore, the combinations of wild type 
RANTES with C37  (1 to 1 ratio) and RANTES with T-20 (1 to 1 ratio) were assessed 
for fusion inhibition.  As shown in Table 5-1, RANTES alone produced an IC50 for 
inhibition of 109 ±126 nM, C37 alone had an IC50 of inhibition of 8.33 ±1.21 nM, and a 
combination inhibited at 2.32 ±0.34 nM.  This modest but repeatable effect was assessed 
using the combination index formula described by Chou and Talalay (212).  The 
combination index (CI) of a two drug combination can be used to study the interactions 
of two drugs where 1 indicates no synergy between the two drugs (that is, their effects 
are merely additive), and values lower than 1 indicate synergy, with values closer to zero 
indicating more synergy.  The combination of RANTES and C37 showed moderate 
synergy, with a CI value of 0.3056 (Table 5-1).  Similarly, RANTES in combination 
with T-20 showed modest synergy, giving a CI value of 0.3442.   
     The RANTES variant “P2-RANTES” was discovered by Hartley et al  who used 
phage selection of randomly N-terminally mutated RANTES to discover this analog that 
tightly binds CCR5 and internalizes the receptor with high efficiency (100).  P2-
RANTES performs quite well in fusion assays, having an IC50 of 0.88nM in our hands 
(Figure 5-3) and 0.6-0.9 nM as reported by Hartley (100). However, in a 1:1 
combination of P2-RANTES with C37, the IC50 of inhibition drops to 0.008 nM, giving 
a CI value of 0.01 (Figure 5-3 and Table 5-1).  This value indicates a highly synergistic  
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              Figure 5-3: The dose dependent inhibition curve in the R5-tropic cell-cell fusion 
assay for combination of P2-RANTES with C37 or T-20. The free C37 (red open 
triangle), free T-20 (black open circle), free P2-RANTES (purple open square),  
C37 combination (1 to 1 ratio) with P2-RANTES (pink plus) and T-20 combination 
(1 to 1 ratio) with P2-RANTES (blue cross) are presented using the plot of the 
percentage of fusion in the HeLa-ADA and HeLa-P5L R5 tropic cell-cell fusion 
assay versus the concentration (nM). 
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and potent combination.  Similarly, the combination of P2-RANTES and T-20 also 
resulted in high synergy and effectiveness (Figure 5-3 and Table 5-1). 
     To determine which ratio of P2-RANTES and C37 best inhibits HIV-1 fusion, ratios 
of 20:1, 10:1, 1:1 and 1:10 were also tested.  As shown in Table 5-2, the ratio of P2-
RANTES:C37 10:1 has an IC50 of 0.001 nM, with a CI of  0.0025.  To our knowledge, 
this is the most potent combination of fusion inhibitors yet reported, both in terms of 
concentration for effectiveness and in terms of the CI value. 
     Interestingly, the combination between C37 and T-20 also showed a moderate 
synergistic effect, with a CI of 0.49. As shown in Table 5-1, the 1:1 ratio of C37/T20 
combination has an IC50 of 0.63 ± 0.21 nM, where C37 alone and T-20 alone only gave 
IC50 of 8.33 ± 1.21 nM and 1.65 ± 0.79 nM, respectively.  This may indicate that the two 
peptides have different functions in HIV inhibition.  While it is generally postulated that 
both C37 and T-20 bind to the N-terminal coiled coil of gp41, a recent report suggests 
that T-20 may have alternate binding modes (104). 
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Table 5-2: Combination index values and dose reductions for inhibition of HIV-1 (ADA) 
env mediated cell –cell fusion with combination of P2-RANTES and C37 with different 
molar ratio.  
 
 
P2-RANTES C37 
Concentration 
(nM) 
Concentration 
(nM) 
 
Ratio of 
P2-
RANTES 
/C37 
 
% of 
Inhibition 
 
 
CI 
Alone Mix 
 
DRI 
Alone Mix 
 
DRI 
95 0.011 53.1 0.56 94 284 0.028 10100 
90 0.0089 18.7 0.16 113 77.3 0.0083 9370 
70 0.0065 2.82 0.018 158 7.37 0.00089 8250 
 
 
20:1 
50 0.0053 0.861 0.0044 195 1.68 0.00022 7620 
95 0.010 12.64 0.12 105 16.1 0.012 1330 
90 0.0071 5.36 0.036 149 8.94 0.0036 2480 
70 0.0037 1.14 0.0041 279 3.10 0.00041 7620 
 
 
10:1 
50 0.0025 0.429 0.0010 415 1.59 0.000103 15400 
95 0.068 12.6 0.47 27 16.1 0.47 34 
90 0.047 5.35 0.16 34 8.94 0.16 57 
70 0.025 1.13 0.021 54 3.10 0.021 148 
 
 
1:1 
50 0.018 0.43 0.0059 72 1.59 0.0059 267 
95 0.061 12.6 0.087 145 16.1 0.87 18 
90 0.051 5.35 0.039 137 8.94 0.39 23 
70 0.038 1.14 0.0093 123 3.10 0.092 34 
 
 
1:10 
50 0.032 0.43 0.0037 115 1.59 0.037 43 
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Figure  5-4: HIV (Ba-L) infection assay of combination of P2-RANTES with C37 (10 to 1 
ratio). The free C37 (black), free P2-RANTES (orange) or C37 combination with P2-
RANTES (with P2-RANTES /C37=10:1 ratio, purple) are presented using the plot of the 
percentage of inhibition versus the concentration (nM) in the HIV-1 strain Ba-L infection 
assay. Error bars indicate the triplicate standard deviation (±SD). Curves were fitted with 
four-parameter logistic equation (187) using KaleidaGraph.  
 
 
Table 5-3: Combination index values and dose reductions for inhibition of HIV-1 (Ba-L) 
infection assay with combination of P2-RANTES with C37 (10 to 1 ratio). 
 
P2-RANTES C37 
Concentration 
(nM) 
Concentration 
(nM) 
% of 
Inhibition of 
HIV (Ba-L) 
infection  
 
 
 
CI 
Alone Mix  
 
DRI 
Alone Mix  
 
DRI 
95 0.014 39.52 0.55 72 344.79 0.054 6270 
90 0.017 26.49 0.44 60 187.48 0.044 4265 
70 0.023 12.86 0.29 44 62.36 0.029 2125 
50 0.029 8.17 0.23 36 31.25 0.023 1373 
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HIV-1 infection assays 
     The best combination studied from the cell-cell fusion assay, P2-RANTES and C37 
with fixed ratio as 10:1, was tested for inhibitory capacity against HIV-1 (Ba-L) in 
PBMC.  As shown in Figure 5-4, P2-RANTES and C37 were each effective inhibitors, 
as reported previously (95,100,104).  The combination of P2-RANTES and C37 (10 to 1 
ratio) shows 90% inhibition at 0.48 nM and the CI of 0.016 (Table 5-3). This indicates 
that combination of P2-RANTES and C37 indeed gives strong synergy in the real HIV 
infection assay as well as the in vitro cell-cell fusion assay. 
FACS analysis  
     In order to study the mechanism of this strong synergy between P2-RATNES and 
gp41 binding peptides, we hypothesized that the internalization of CCR5 to remove it 
from the cell surface by P2-RANTES may play an important role. As published by 
Hartley et al.(100), P2-RANTES not only tightly binds to CCR5 as other chemokines do, 
but also strongly internalizes the CCR5 on the cell surface. We used steady-state CCR5 
down-modulation FACS experiments to study the internalization of CCR5 by treatment 
with individual or combination drugs in 30 min of incubation at 37ºC. As shown in 
Figure 5-5, free C37 or free wild type RANTES did not induce significant CCR5 
internalization with the highest concentration (100 nM), but free P2-RANTES or P2-
RANTES combined with C37 (1:1 ratio) showed significant internalization of CCR5 in a 
concentration dependent manner.  This significant difference between wild type 
RANTES and P2-RANTES may play a role in the stronger synergy observed by P2-
RANTES:C37 compared to wild type RANTES:C37. 
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Figure 5-5: CCR5 internalization, as measured by FACS.  The effect of free C37, P2-
RANTES and the combination of wild type RANTES/ C37 (1:1 ratio) and P2-RANTES/C37 
(1:1 ratio) on the cell surface CCR5 population was measured. Data are plotted as 
histograms of fluorescence intensity (cell surface CCR5), with the cell number normalized 
for each sample. The level of CCR5 expression is represented for cells treated with: 0 nM 
drug (black, shaded), 1 nM (brown), 10 nM (blue) and 100nM (green). The cells stained 
with the second antibody but in the absence of CCR5 antibodies are shaded in light gray. 
Each histogram represents between 9000 and 9400 viable cells. Viability of the cells 
varied from 95% to 97%. 
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Discussion 
     HIV-1 entry in cells requires cell surface proteins CD4 and coreceptor CCR5 or 
CXCR4 (215-218).  CCR5 serves as the main coreceptor for transmitting infection of 
HIV-1 (219-221), and  CCR5 density level (molecules/cell) on CD4 T cells have been 
shown to be the driving force of cell-cell fusion (211,222,223). Reeves et al (224,225) 
have shown that “low” CCR5 density levels on cell lines lead to slower kinetics of 
fusion and increased susceptibility to T-20.  In addition, CCR5 levels were shown to 
affect sensitivity of primary cells to T-20 (226).  Rapamycin, which reduces CCR5 
density oncells, was recently shown to moderately synergize with T-20, giving a dose 
reduction in T-20 of about 33-fold (227) 
     Synergy between drug therapies is an important strategy to allow effective disease 
control at low doses of drug (202,203,205-208,228,229).  Several combinations of anti-
HIV compounds have been reported that involve fusion inhibitors, including CCR5 
antibodies, CCR5 antagonists and fusion inhibitors (13, 23, 37, 38).  Among the best of 
these, PRO 542 (a multivalent CD4-immunoglobulin fusion) and T-20 were shown to 
have strong synergy with a combination index value of 0.34 at 50% inhibition in a cell-
cell fusion assay (205).  Even better synergy was reported by Safarian et al. who 
observed a CI50 of 0.06 for the combination of anti-CCR5 antibody PA14 and small 
molecule SCH-C (206).  However, these authors do not report a dose reduction and the 
combination appears to work no better than nanomolar levels.  
      We report here an even more effective combination of anti-HIV agents, namely the 
combination of P2-RANTES and the gp41-binding peptide C37 in a ratio of 10:1.  This 
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combination shows highly potent anti-HIV activity both in fusion assays and against 
viral infection in PBMC, which gave a CI value of 0.0025 in the cell-cell fusion assay 
and 0.029 in the HIV infection assay (50% inhibition).  This combination was found 
giving a dose reduction in T-20 of about 1373-fold (50% inhibition) (Table 3). To our 
knowledge, the synergy observed using these combinations is far greater than for any 
other combination of fusion inhibitors yet reported.  Since FACS analysis shows that P2-
RANTES greatly decreases cell surface CCR5 on HeLa-TZM cells, overall this suggests 
that chemokine-mediated internalization of CCR5 strongly increases the sensitivity of 
HIV-1 to inhibition by C37/T20. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
     The chemokine monomeric fold can support very different dimer forms: CC 
chemokine and CXC chemokine subfamily. Both rational and random mutagenesis were 
used to study chemokine monomers and dimerization.  A novel use of a bacterial 
homodimer selection system geared toward understanding quaternary structure 
formation in chemokines is reported. The results indicate that, while the goal of attaining 
folded monomeric variants from the wild type chemokine dimer is achievable, neither 
structure based design of mutations nor a λ repressor based homodimer selection system 
was successful in revealing a pathway to obtain a CC chemokine-type dimer from a 
monomeric CXC chemokine, or a CXC chemokine-type dimer from a CC chemokine 
monomer.  When expressed and purified, all folded variants were judged to be 
monomers, not dimers.  It can be concluded that the chemokine fold is a robust 
arrangement that can be attained by a wide variety of amino acid sequences, while the 
chemokine dimer can only be formed by very specific placement of amino acids.  
However, further design and investigation of chemokine quaternary forms may be 
possible using computational methods and phylogenetic calculations. 
     The dimer of MIP-1β does not bind to CCR5.  Since the dimer of chemokine is very 
important in several in vivo studies. We used a “trapped dimer”, MIP-1β-A10C,  to study 
whether the dimer CC chemokine has ability to bind or activate its receptor. Our data 
indicate that dimer of the CC chemokine does not bind or activate the CCR5 receptor 
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even though it fully retain the ability to bind GAGs. This result supports a model of 
chemokine action in which the chemokine is immobilized on the endothelial surface in 
the dimeric (or higher order oligomeric) form by binding to cell surface GAGs. The 
ability to dimerize is likely critical for GAG affinity, for chemokine gradient formation, 
or for the ability of the chemokine to be presented appropriately to the receptor on the 
surface of a chemotaxing leukocyte that is passing nearby.  Dissociation of the 
chemokine oligomer into monomeric subunits likely occurs as part of the process of 
transferring the chemokine from the GAG to the receptor.  This dissociation from the 
dimer (or oligomer) form to the monomer form is evidently necessary in order to bind 
and activate the cognate receptor, at least in the case of CC chemokines, as shown by the 
present work on the CC chemokine MIP-1β. 
     Unique structure of N-terminal six-site mutant of RANTES: P2-RANTES.  We 
produced the previously reported potent anti-HIV-1 protein P2-RANTES from E. coli 
and found this unique mutant protein to have ~6000 fold improvement in the 3T3 
completive cell-cell fusion comparing to the widely used HIV fusion inhibitor, T-20. 
The crystal structure of this mutant protein was determined at 1.7Å resolution. Several 
contact area were identified by this tetramer crystal structure. This structure study 
illustrated detailed information of this potent anti-HIV-1 chemokine mutant protein.   
     Synergistic effect of P2-RANTES and C37.   CCR5 serves as the main coreceptor for 
transmitting strains of HIV-1 in primary infection. In this Ph.D. study, we demonstrate 
that treatment of CD4+ CCR5+ cells with P2-RANTES combined with C37 or T-20 
resulted in significant suppression of HIV-1 entry, both in cell-cell fusion assay and HIV 
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infection assay of PBMC. Further FACS analysis suggested that the reason for the 
synergy is that P2-RANTES has a strong internalization on CCR5 expression on the 
HeLa-TZM cell while wild type RANTES has a modest effect in the same experiment. 
The significant difference between wild type RANTES/C37 and P2-RANTES/C37 
suggests that the strong internalization of CCR5 by P2-RANTES makes the combination 
of P2-RANTES/C37 more synergistic than wild type RANTES/C37.   
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NOMENCLATURE 
 
 
                     AIDS                    Acquired Immune Deficiency Syndrome 
                     AOP                     aminooxypentane 
                     AUC                     analytical ultracentrifugation 
                     BSA                      bovine serum albumin 
                     BME                    β-mercaptoethanol 
                     B.M.                    Bachelor of Medicine 
                     CCR                    CC chemokine receptor 
                     CXCR                 CXC chemokine receptor 
                     CHO                    Chinese hamster ovary 
                     CNS                     Crystallography and NMR system 
                     CRPG                  chlorphenol red-β-D-galactopyranoside 
                     DTT                     dithiothreitol 
                     EDTA                  EthyleneDiamineTetraacetic Acid  
                     NNY                    N-nonanoyl 
                     NOE                    Nuclear Overhauser Effect  
                     PSC                     [L-ThiaPro2, L-α-cyclohexyl-Gly3]-NNY  
                     Da                        Dalton 
                     DSS                     4, 4-dimethyl-4-silapentane-1-sulfonate  
                     DMEM                Dulbecco’s Modified Eagle’s Medium  
                     EC50                     concentration of 50% effect (i.e. activation) 
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                     env                       HIV-1 envelope protein  
                     FACS                  fluorescence activated cell sorting 
                     FCS                     fetal calf serum  
                     FDA                    Food and Food Administration 
                     FITC                   fluorescein isothiocyanate 
                     FBC                    fetal bovine serum 
                     GAG                   glycosaminoglycan 
                     HPLC                 High Performance Chromatography 
                     HIV                     human immunodeficiency virus 
                     HSQC                 heteronuclear single-quantum coherence 
                     IC50                     concentration of 50% inhibition 
                     IL-8                     interleukin-8 (CXC chemokine Ligand 8 or CXCL8)  
                     IPTG                   isopropyl-β-D-thiogalactopyranoside 
                     Kd                       dissociation constant 
                     MALDI-TOF     Matrix Assisted Laser Desorption /Ionization- Time Of             
                                                  Flight  
                     MCP                   monocyte chemotactic protein, MCP-1(CCL2), MCP-2  
                                                 (CCL8), MCP-3 (CCL7) are mentioned in this thesis 
                     MIP                    macrophage inflammatory protein (MIP-1α, CCL4; MIP- 
                                                 1β, CCL3) 
                     MW                    Molecular Weight  
                     NMR                  nuclear magnetic resonance 
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                     PBS                    phosphate buffered saline  
                     PBMC                peripheral blood mononuclear cells  
                     PCR                    polymerase chain reaction 
                     PEEA                 Polyethyleneamine 
                     PEG                    polyethylene glycol 
                     PF-4                    platelet factor 4 (CXCL4) 
                     PI                        propidium iodide 
                     RANTES            regulated on activation of normal T cell expressed and  
                                                 secreted (CCL5) 
                    RMSD                 root mean square deviation 
                    RPMI                  Roswell Park Memorial Institute  
                    SD                        Standard deviation 
                    SDS-PAGE         sodium dodecyl sulfate polyacrylamide gel  
                                                electrophoresis 
                    SDF-1α               stromal cell-derived factor-1α (CXCL12) 
                    TFA                     Trifluroacetic acid 
                    WT                       Wild Type  
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